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Abstract
Eight- and four-membered analogues of N-butyldeoxynojirimycin (NB-DNJ), a reversible male
contraceptive in mice, were prepared and tested. A chiral pool approach was used for the synthesis
of the target compounds. Key steps for the synthesis of the eight-membered analogues involve:
ringclosing metathesis and Sharpless asymmetric dihydroxylation, and for the four-membered
analogues: Sharpless epoxidation, epoxide ring opening (azide), and Mitsunobu reaction to form
the four-membered ring. (3S,4R,5S,6R,7R)-1-Nonylazocane-3,4,5,6,7-pentaol (6), was moderately
active against rat-derived ceramide-specific glucosyltransferase and four of the other eight-
membered analogues were weakly active against rat-derived β-glucosidase 2. Among the four-
membered analogues, ((2R,3s,4S)-3-hydroxy-1-nonylazetidine-2,4-diyl)dimethanol (25),
displayed selective inhibitory activity against mouse-derived ceramide-specific
glucosyltransferase and was about half as potent as NB-DNJ against the rat-derived enzyme. ((2S,
4S)-3-Hydroxy-1-nonyl-azetidine-2,4-diyl)dimethanol (27) was found to be a selective inhibitor of
β-glucosidase 2, with potency similar to NB-DNJ. Additional glycosidase assays were performed
to identify potential other therapeutic applications. The eight-membered iminosugars exhibited
specificity for almond-derived β-glucosidase and the 1-nonylazetidine 25 inhibited α-glucosidase
(Saccharomyces cerevisiae) with an IC50 of 600 nM and β-glucosidase (almond) with an IC50 of
20 µM. Only N-nonyl derivatives were active, emphasizing the importance of a long lipophilic
side chain for inhibitory activity of the analogues studied.
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Hormonal male contraceptive agents are currently in clinical trials, but have not yet reached
the market due to side effects, and pharmacokinetic issues.1 The discovery and development
of non-hormonal contraceptive agents is another approach towards male contraception.2
Non-hormonal experimental agents such as gossypol3 and alpha-chlorohydrin4 have been
studied, but they are neither safe nor effective enough for human use. Among newer non-
hormonal contraceptive lead compounds,5 the alkylated iminosugar N-
butyldeoxynojirimycin (NB-DNJ, Zavesca®) has been reported to be an effective, reversible,
and non-toxic oral male contraceptive agent in mice (Figure 1).6 NB-DNJ is in clinical use
for the treatment of mild-to-moderate type 1 Gaucher’s disease in adult patients who cannot
be treated with enzyme replacement therapy (ERT).7
The iminosugar NB-DNJ (Figure 1) is an inhibitor of ceramide-specific glucosyl
transferase,8 and β-glucosidase 2, which are key enzymes (Figure 1 and Table 1) in the
biosynthesis of glycosphingolipids.9,10 Inhibition of these enzymes leads to an imbalance of
testicular glucosylceramide levels, which is believed to impair spermatogenesis. The effect
of NB-DNJ on spermatogenesis was found to be species- and strain-specific.11 NB-DNJ is
active in C57B1/6J-related mouse strains but not in other mouse strains or in rabbits.
Although NB-DNJ also showed no discernible effects on human spermatogenesis,12 we
hypothesized that analogues of NB-DNJ with higher potency and or differential enzyme
selective inhibitory activity could be discovered that would affect spermatogenesis in
mammalian species other than C57B1/6J-related mouse strains, including man.
Five-, six- and seven-membered NB-DNJ analogues13 have been reported as inhibitors for
ceramide-specific glucosyltransferase, but none of them are significantly better inhibitors
than NB-DNJ except N-alkyloxyalkyl DNJ analogues14 including adamantane-DNJ
conjugates.15 Six- and seven-membered ring DNJ analogues have also been investigated for
pharmacological chaperoning to improve protein folding and trafficking defects in
Gaucher’s disease.16 More potent analogues and derivatives effective in all mammalian
species could possibly be obtained by structural changes of the parent compound, which
includes ring-enlarged or ring-contracted analogues related to NB-DNJ such as azocane
analogues (eight-membered ring) and azetidine analogues (four-membered ring). A series of
azetidine analogues were recently reported as inhibitors of various glycosidases,17 but they
were not tested against ceramide-specific glucosyltransferase. We report herein the design
and synthesis of novel eight-membered and four-membered iminosugar analogues and the
evaluation of their inhibitory potencies for testicular ceramide-specific glucosyltransferase,
testicular β-glucosidase 2, and other glycosidase enzymes. The key synthetic steps for the
synthesis of the eight-membered analogues involved a ring closing metathesis and a
Sharpless asymmetric dihydroxylation. The four-membered iminosugars were prepared from
L-gulono-1,4-lactone or 1,2:5,6-diisopropylidene-D-mannitol, employing as the key steps a
Sharpless epoxidation and a Mitsunobu reaction for ring formation.
Results/Discussion
Design and synthesis of eight-membered iminosugars
Molecular models of eight-membered iminosugars 2, 4, and 6 (Figure 2) were generated
using Maestro (Schrödinger, LLC). The ceramide structure was prepared based on the
crystal structure of galactosylceramide.13a, 18
Figure 3a shows the overlay of NB-DNJ and ceramide.13a Overlay of compound 2 with NB-
DNJ (Figure 3b) demonstrates that the 4-hydroxyl, 3-hydroxyl and the 2-hydroxymethyl
groups of NB-DNJ have a similar orientation as the 5-hydroxyl, 4-hydroxyl and 3-hydroxyl
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groups of compound 2 respectively. The introduction of a double bond into the 8-membered
ring slightly changes the ring conformation (compounds 3 and 4). Nevertheless, overlay of
compound 4 with NB-DNJ (Figure 3c) was very similar to that of compound 2. Next, two
additional hydroxyl groups were added to the ring (compounds 5 and 6) and then assessed
for structural similarity to NB-DNJ. In the overlay of compound 6 with NB-DNJ (Figure
3d), the 7-hydroxyl group of compound 6 is close to the 5-hydroxyl group of NB-DNJ. The
6- hydroxyl group of 6, however, does not overlay with any of the hydroxyl groups in NB-
DNJ. The modeling study reveals that the designed six eight-membered iminosugars possess
structural similarities with NB-DNJ and therefore could be expected to be inhibitors of the
targeted enzymes.
The retrosynthetic approach for the synthesis of the eight-membered iminosugars is outlined
in Scheme 1. The six target compounds would be prepared from common intermediate 7,
which could be formed through a ring closing metathesis of diene 8. Diene 8 would be
generated by a reductive amination of aldehyde 9 with allylamine.
Compound 9 was prepared as shown in Scheme 2, utilizing known procedures.19,20 The
primary hydroxyl group of methyl-α-D-glucopyranoside (10) was protected as its TBS ether
11. Benzylation of intermediate 11 provided the fully protected compound 12, which was
desilylated with TBAF to afford the primary alcohol 13. Iodination of alcohol 13 was
performed with iodine and triphenylphosphine to provide the iodo intermediate 14, which
underwent reductive ring opening with activated zinc under sonication conditions21 to
furnish aldehyde 9 in good yield.
The synthesis of the eight-membered ring was performed as shown in Scheme 3. Reductive
amination22 of aldehyde 9 with allylamine using NaBH(OAc)3 afforded diene 15. The
secondary amine of the diene was protected with a tosyl group to yield compound 8a. Ring
closing metathesis (RCM)23 was then performed using the Grubbs II catalyst to obtain the
eight-membered ring 7a.
The amino group of intermediate 15 was also protected with a Boc group to provide
compound 8b (Scheme 4) although in a slightly lower yield than the N-tosylation reaction of
15. RCM reaction of 8b yielded compound 7b as a mixture of two Boc-rotamers in a ratio of
1: 1.4. This reaction provided the targeted compound 7b in slightly better yield than the
reaction of N-tosyl derivative 8a to form RCM product 7a.
With key intermediates 7a and 7b in hand, the tri-hydroxy compounds 1–4 were obtained as
shown in Scheme 5. The tosyl group of compound 7a was cleaved using Na and naphthalene
to provide secondary amine 16.24 Amine 16 was also prepared from intermediate 7b by
removal of the Boc group. Removal of the Boc group provided a slightly higher yield than
the deprotection of the tosyl group. Comparing the two protecting groups in this reaction
sequence reveals that the N-tosyl and N-Boc protecting groups lead to the same overall yield
for the synthesis of intermediate 16 from 15. Reductive alkylation of the secondary amine22
16 was carried out next, using butyraldehyde and nonyl aldehyde to afford compounds 17a
and 17b respectively. Debenzylation and double bond reduction was achieved with
hydrogen gas, using palladium (II) chloride as the catalyst, to obtain target compounds 1 and
2. Reductive debenzylation25 of compounds 17a and 17b was performed using Li and
naphthalene to provide the tri-hydroxy derivatives 3 and 4.
The synthesis of pentahydroxy derivatives 5 and 6 was also achieved from common
intermediate 7a (Scheme 6). First, the cis-diol moiety was introduced into compound 7a by
a catalytic Sharpless cisasymmetric dihydroxylation26 to provide diol 18. A non-asymmetric
dihydroxylation was also performed using OsO4, but the reaction provided an inseparable
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mixture of reaction products. Diol 18 was then benzylated to form pentabenzyl ether 19.
Benzylation of 18 provided advantages such as clean reactions and ease of purification in
the following reaction steps. Reductive detosylation of 19 gave secondary amine 20.
Reductive alkylation of the secondary amine was performed using butyraldehyde and nonyl
aldehyde to furnish compounds 21a and 21b respectively. Finally, hydrogenolysis of
compounds 21a and 21b afforded the corresponding penta-hydroxyazocanes 5 and 6. The
structure of penta-hydroxyazocane 6 was confirmed by single crystal X-ray crystallography
(Figure 4).
Design and synthesis of four-membered iminosugar analogues
Six four-membered iminosugars, 22–27, were designed and synthesized (Figure 5).
As shown in Figure 6, using Maestro (Schrödinger. LLC) NB-DNJ was overlaid with
compounds 23, 25 and 27 (Figures 6a, 6b and 6c respectively). Compound 25 was also
overlaid with ceramide (Figure 6d). The 2-hydroxymethyl, 3-hydroxyl, and 4-
hydroxymethyl groups of compound 23 align well with the 4-hydroxyl, 3-hydroxyl, and 2-
hydroxymethyl groups of NB-DNJ (Figure 6a). As for compound 25, only the 4-
hydroxymethyl group was not aligned with NB-DNJ. Overlay of NB-DNJ with compound
27 shows that the 2-hydroxymethyl and the 3-hydroxyl groups are close to the 4-hydroxyl
and 3-hydroxyl groups of NB-DNJ respectively. Compound 25 aligned very well with
ceramide (Figure 6d, N-acyl chain, N, C2, C3 and the 3-hydroxyl group). Compound 23
aligned well with ceramide similar to compound 25 (picture not shown). The only difference
between compound 23 and 25 is the stereochemistry at C4. As a result of the modeling
study, we concluded that the designed six four-membered iminosugars are good structural
mimics of NB-DNJ and ceramide.
The synthesis of the four-membered iminosugars (Scheme 7) started by subjecting L-
glyceraldehyde acetonide (28) to a Wittig reaction, followed by DIBAL-H reduction to
furnish allylic alcohol 29. Sharpless epoxidation and protection of the hydroxyl group
provided epoxide 30. Next, the epoxide was opened with sodium azide, and then the
secondary hydroxyl group was benzylated to yield benzyl ether 31. The azide group was
reduced with LiAlH4 and the resulting amino group was reacted subsequently with tosyl
chloride to form tosylate 32. The acetonide protecting group of intermediate 32 was
removed and the primary alcohol was next converted to silyl ether 33. Ring closure to the
four-membered ring was accomplished by a Mitsunobu reaction, which was followed by
reductive removal of the N-tosyl group to furnish azetidine 34. Azetidine 34 was subjected
to reductive amination with butyraldehyde and nonyl aldehyde followed by desilylation to
afford intermediates 35a and 35b. Hydrogenolysis of the benzyl protecting groups yielded
the targeted four-membered (2R,4R)-3-hydroxyazetidines 22 and 23.
Starting with known epoxyacetonide 36 and following the same synthesis procedures as
shown in Scheme 7 furnished the (2R,3s,4S)-3-hydroxyazetidines 24 and 25 (Scheme 8).
Similarly, starting from epoxyacetonide 42 and following the same procedures shown above
in Schemes 7 and 8, the (2S,4S)-3-hydroxyazetidines 26 and 27 were prepared (Scheme 9).
Enzyme Inhibition Studies
Compounds 1–6 and 22–27 were tested (Table 1) for inhibition of ceramide-specific
glucosyltransferase derived from C57BL/6 mouse and Long Evans (LE) rat testicular
microsomes and LE rat-derived testicular β-glucosidase 2. NB-DNJ was used as the positive
control. Compounds 1–5, 22–24 and 26–27 did not inhibit rat or mouse ceramide-specific
glucosyltransferase; however, N-nonylazocane derivative 6 showed moderate inhibition
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(IC50 = 127 µM) of the rat-derived ceramide-specific glucosyltransferase (Table 1). N-
Nonylazetidine derivative 25 was as active as NB-DNJ against mouse-derived ceramide-
specific glucosyltransferase (IC50 = 44 µM) and moderately active against rat-derived
ceramide-specific glucosyltransferase (IC50 = 91 µM). The result suggests that the C6 and
C7 hydroxyl groups and the longer alkyl chain in the eight-membered analogue 6 are
important for activity. As shown with the overlays in Figure 3, the 7-hydroxyl group of
compound 6 matches the 5-hydroxyl group of NB-DNJ. This structural similarity with NB-
DNJ could be the reason why compound 6 is moderately active. Our results also show that a
longer N-alkyl group is important for inhibition of this enzyme by eight-membered analogue
N-nonyl-6 and four-membered analogue N-nonyl-25 because the corresponding N-butyl
analogues 5 and 24 are inactive compounds. In the overlay shown in Figure 6d, between
compound 25 and ceramide, the N-alkyl chain and the N-C2-CH2OH bond of 25 align well
with the N-acyl chain and the N-C2-C3-OH bond of ceramide, which could be the reason
why this is the most active compound in the series. In case of compound 23, even though the
N-alkyl chain and the N-C2-CH2OH bond align with ceramide (picture not shown), the
stereochemistry of the 4-hydroxymethyl group seems to prevent inhibition.
When tested for inhibitory activity against β-glucosidase 2, compounds 1, 5, and 22–26 did
not show inhibitory activity, whereas compounds 2, 3, 4 and 6 exhibited weak activities. The
IC50 values for these compounds are 803, 1123, 904 and 766 µM respectively. The three N-
nonyl analogues 2, 4, and 6 were more potent then the corresponding N-butyl derivatives 1,
3, and 5. N-Nonyl-azetidine 27 inhibited rat testicular β-glucosidase 2 at 70 µM, which is
similar to the inhibitory activity of the positive control NB-NDJ. This result suggests that the
azetidine stereochemistry and a long alkyl chain, such as the nonyl group are important for
inhibitory activity. Interestingly, the N-nonylazocane 6 exhibited activities in both the
ceramide-specific glucosyltransferase assay and the β-glucosidase assay.
Iminosugars are already used and also hold promise as modulators of carbohydrate-
processing enzymes for various therapeutic applications such as Gaucher’s disease, cystic
fibrosis, Niemann Pick disease, diabetes, viral disease, Pompe’s disease, Fabry’s disease and
Parkinson’s disease.8, 27 In addition, so-called immucillins are in clinical trials for the
treatment of T- and B- cell cancers and autoimmune diseases.28 Therefore, we further
evaluated the inhibitory properties of the new iminosugars towards other readily available
glycosidases (Table 2). The following enzymes were investigated: α-glucosidase
(Saccharomyces cerevisiae), β-glucosidase (almond), α-galactosidase (green coffee beans),
β-galactosidase (Escherichia coli), α-mannosidase (jack bean) and β-mannosidase (Roman
snail). As positive controls for the glycosidase inhibition assays, the following standard
compounds were used:29 DNJ (1-deoxynojirimycin) and NB-DNJ (N-
butyldeoxynojirimycin) for the α-glucosidase assay; castanospermine for the β-glucosidase
assay; DGJ (1-deoxygalactonojirimycin) and NB-DGJ (N-butyldeoxygalactonojirimycin)
for the α-galactosidase and β-galactosidase assays; DMJ (1-deoxymannojirimycin) for the
α-mannosidase and β-mannosidase assays. The results are summarized in Table 2. In these
assays we determined the % remaining activity of the enzymes in the presence of 100 µM of
the iminosugars and also their IC50 values (µM).
We found that eight-membered compounds 1–4 were modest inhibitors of β-glucosidase
(IC50 = 87–134 µM). Compounds 5 and 6 showed weak inhibition against β-glucosidase (87
and 85% remaining activity at 100 µM). All of the eight-membered compounds showed
weak inhibition against α-glucosidase and β-galactosidase (81~98% remaining activity at
100 µM), and little or no inhibitory activity towards α-galactosidase and mannosidases.
Even though the activities were moderate or weak, eight-membered iminosugars exhibited
specificity for β-glucosidase. When the activities of compounds 1–4 towards β-glucosidase
were compared, the length of the N-alkyl group did not show much difference in the activity
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(IC50 values, 87 versus 92 µM, and 105 versus 134 µM). The four-membered analogues
showed specificity towards α-glucosidase and β-glucosidase. Compound 25 was the most
potent compound tested. At 100 µM concentration α-glucosidase activity was inhibited
completely and only 26% activity of β-glucosidase remained. The IC50 values were 0.6 µM
and 20 µM respectively. A similar trend was observed for the inhibition of α- and β-
galactosidase by 25 but with greatly reduced inhibitory potency. Compound 24 was a
moderate inhibitor of α-glucosidase (65% remaining activity) and compound 27 a moderate
inhibitor of α-galactosidase (57% remaining activity). Compound 26 had weak β-
glucosidase inhibitory activity (82% remaining activity at 100 µM). Compounds 22 and 23
displayed no inhibitory activities. Of note is the observation that N-nonyl-25 was active in
inhibiting α-glucosidase and β-glucosidase activity, whereas the corresponding N-butyl
analog 24 did not show significant activity in these assays.
In conclusion, we have designed and synthesized novel eight- and four-membered
iminosugars as potential male contraceptive agents. The N-alkyl iminosugar analogues were
tested for inhibitory activities against testicular ceramide-specific glucosyltransferase,
testicular β-glucosidase 2 and other glycosidases. Among the eight-membered analogues,
only the N-nonylpentanol derivative 6 was moderately active against rat-derived ceramide-
specific glucosyltransferase. N-Nonylazetidine 27 was the most potent inhibitor of testicular
β-glucosidase 2, on par with the positive control NB-DNJ. Unlike NB-DNJ, azetidine 27 is a
selective inhibitor of β-glucosidase 2 since this derivative does not inhibit ceramide-specific
glucosyltransferase. Compounds 1–4 exhibited modest activity against β-glucosidase from
almonds. N-Nonylazetidine 25 was found to be a specific inhibitor of mouse- and rat-
derived ceramide-specific glucosyltransferase that did not inhibit testicular β-glucosidase 2.
Compound 25 was also an effective inhibitor of α-glucosidase and a moderately active
inhibitor of almond β-glucosidase. The studies revealed that penta-hydroxy substitution and
the N-nonyl group are important for the activity of the eight-membered analogue 6 for the
testis-specific enzymes. In the series of four-membered analogues a stereochemical bias for
the meso-25 compound for inhibition of the testis-derived ceramide-specific
glucosyltransferases was observed. The N-nonyl group was important for the activity for the
two most potent compounds, 6 and 25, because their corresponding N-butyl derivatives 5
and 24 were inactive in all assays.
Experimental Section
General procedures
Commercially available chemicals were used as purchased without further purification. All
solvents were dried over an activated alumina column before use except commercially
available anhydrous 1,2-dimethoxyethane and 1,2-dichloroethane. All reactions with air- or
moisture-sensitive reagents were carried out under a nitrogen atmosphere. The 1H NMR
spectra were obtained on a 400 MHz spectrometer. For 1H NMR spectra, the chemical shifts
are referenced to the tetramethylsilane (TMS) peak as an internal standard or the residual
solvent peak. The 13C NMR spectra were recorded at 100 MHz. Chemical shifts are reported
in ppm and were referenced to the appropriate residual solvent peak. High-resolution mass
spectra (HRMS) were recorded with electron-spray ionization. IR spectra were taken on a
FT-IR spectrometer. Optical rotations were measured on a polarimeter. Flash column
chromatography was performed on silica gel (230–400 mesh).
Methyl-6-O-(tert-butyldimethylsilyl)-α-D-glucopyranoside (11)
To a solution of methyl-α-D-glucopyranoside 10 (20.0 g, 102 mmol) in DMF (160 mL) at 0
°C was added imidazole (17.4 g, 256 mmol) followed by tert-butyldimethylsilyl chloride
(18.5 g, 123 mmol). The reaction mixture was stirred for 16 h at room temperature. DMF
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was removed through vacuum distillation and the residue was taken up in EtOAc (1500
mL). The solution was washed with water (3 × 500 mL) and brine (3 x 500 mL), dried over
anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by
silica column chromatography (100% EtOAc) to afford 11 (22.6 g, 72%) as a white
solid. 1H NMR (400 MHz, CDCl3)δ 4.65 (d, J = 3.8 Hz, 1H), 3.78 (dd, J = 10.6, 4.9 Hz,
1H), 3.72 (dd, J = 10.6, 4.9 Hz, 1H), 3.63 (td, J = 9.1, 2.6 Hz, 1H), 3.50 (dt, J = 9.8, 4.9 Hz,
1H), 3.42 (m, 2H), 3.32 (s, 3H), 3.19 (d, J = 2.2 Hz, 1H), 3.04 (d, J = 2.6 Hz, 1H), 2.34 (d, J
= 9.2 Hz, 1H), 0.81 (s, 9H), 0.00 (s, 6H); 13C NMR (100 MHz, CDCl3)δ 99.1, 74.6, 72.3,
72.1, 70.4, 64.2, 55.3, 25.9, 18.3, −5.4; HRMS (ESI) calcd for [C13H28O6Si + Na]+
331.1547, found 331.1540. The data are in accordance with reported values.30
Methyl-2,3,4-tri-O-benzyl-6-O-(tert-butyldimethylsilyl)-α-D-glucopyranoside (12)
To a solution of compound 11 (8.00 g, 25.9 mmol) in DMF (90 mL) at 0 °C was added
sodium hydride (60% dispersion in mineral oil, 3.84 g, 96.0 mmol) and the mixture was
stirred at 0 °C for 30 min. Benzyl bromide (20.0 g, 117 mmol) was added at 0 °C and the
mixture was stirred at room temperature for 17 h. The reaction mixture was cooled to 0 °C
and MeOH (10 mL) was added dropwise in order to quench excess sodium hydride. The
reaction mixture was poured into water (630 mL) and extracted with Et2O (5 × 130 mL).
The combined organic layers were washed with water (2 × 250 mL) and brine (2×250 mL),
dried over anhydrous Na2SO4, and evaporated under reduced pressure. The residue was
purified by silica column chromatography (EtOAc:hexanes 1:12) to afford 12 as a white
solid (11 g, 72%). %). mp 77–78 °C;  (c 1.00 CHCl3); IR (neat) 3064, 3031, 2928,
2856, ,1949, 1873, 1808, 1748, 1606, 1454, 1360, 1252, 1160, 1092, 1072, 835, 736
cm−1; 1H NMR (400 MHz, CDCl3) δ 7.35–7.20 (m, 15H), 4.93 (d, J = 10.7 Hz, 1H), 4.84
(d, J = 11.2 Hz, 1H), 4.78 (d, J = 10.7 Hz, 1H), 4.75 (d, J = 12.2 Hz, 1H), 4.63 (d, J = 12.2
Hz, 1H), 4.60 (d, J = 11.2 Hz, 1H), 4.57 (d, J = 3.6 Hz, 1H), 3.95 (t, J = 9.2 Hz, 1H), 3.74 (d,
J = 3.1 Hz, 2H), 3.58 (dt, J = 9.9, 3.1 Hz, 1H), 3.48 (m, 2H), 3.32 (s, 3H), 0.84 (s, 9H), 0.00
(s, 6H); 13C NMR (100 MHz, CDCl3) δ 138.8, 138.5, 138.3, 128.4, 128.1, 127.8, 127.7,
127.6, 97.9, 82.2, 80.2, 77.8, 75.9, 75.0, 73.4, 71.5, 62.3, 54.9, 25.9, 18.3, −5.2, −5.4;
HRMS (ESI) calcd for [C34H46O6Si + Na]+ 601.2956, found 601.2975. The data are in
agreement with reported values.31
Methyl-2,3,4-tri-O-benzyl-α-D-glucopyranoside (13)
To a solution of compound 12 (6.62 g, 11.4 mmol) in THF (33 mL) was added
tetrabutylammonium fluoride (1M solution in THF, 23 mL, 23 mmol) and the mixture was
stirred at room temperature for 16 h. The reaction mixture was quenched with water (10 mL)
and then extracted with EtOAc (300 mL). The organic layer was washed with brine (2 × 150
mL), dried over anhydrous Na2SO4, and evaporated under reduced pressure. The crude
product was purified by silica column chromatography (EtOAc:hexanes 1:9 and 1:1) to
afford compound 13 as a white solid (5.3 g, 99%). 1H NMR (400 MHz, CDCl3) δ 7.38–7.25
(m, 15H), 4.99 (d, J = 10.9 Hz, 1H), 4.88 (d, J = 11.0 Hz, 1H), 4.83 (d, J = 10.9 Hz, 1H),
4.80 (d, J = 12.1 Hz, 1H), 4.66 (d, J = 12.1 Hz, 1H), 4.64 (d, J = 11.0 Hz, 1H), 4.57 (d, J =
3.6 Hz, 1H), 4.00 (t, J = 9.3 Hz, 1H), 3.76 (dd, J = 11.6, 2.5 Hz, 1H), 3.68 (dd, J = 15.8, 4.1
Hz, 1H), 3.65 (m, 1H), 3.51 (m, 2H), 3.36 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 138.7,
138.2, 138.1, 128.5, 128.4, 128.1, 128.0, 127.9, 127.6, 98.2, 82.0, 80.0, 77.4, 75.8, 75.0,
73.4, 70.7, 61.9, 55.2; HRMS (ESI) calcd for [C28H32O6 + Na]+ 487.2091, found 487.2101.
The data are in accordance with reported values.20
Methyl-6-deoxy-6-iodo-2,3,4-tri-O-benzyl-α-D-glucopyranoside (14)
To a solution of compound 13 (4.6 g, 9.9 mmol), triphenylphosphine (5.2 g, 20 mmol) and
imidazole (3.4 g, 50 mmol) in toluene (70 mL) was added iodine (5.0 g, 20 mmol). The
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reaction mixture was stirred at 70 °C for 3 h and then cooled to room temperature. The
toluene layer was decanted from the resulting solid, which was then washed with EtOAc
(100 mL). The combined organic solution was concentrated under reduced pressure.
Purification by silica column chromatography (EtOAc:hexanes 1:10 and 1:1) furnished 14 as
a white solid (5.4 g, 94%). 1H NMR (400 MHz, CDCl3) δ 7.38–7.26 (m, 15H), 4.99 (d, J =
10.8 Hz, 1H), 4.94 (d, J = 10.9 Hz, 1H), 4.80 (d, J = 10.8 Hz, 1H), 4.79 (d, J = 12.1 Hz, 1H),
4.68 (d, J = 10.9 Hz, 1H), 4.65 (d, J = 12.1 Hz, 1H), 4.61 (d, J = 3.6 Hz, 1H), 4.01 (t, J = 9.3
Hz, 1H), 3.53 (dd, J = 9.6, 3.6 Hz, 1H), 3.45 (m, 2H), 3.42 (s, 3H), 3.33 (t, J = 9.1 Hz, 1H),
3.28 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 138.5, 138.0, 128.5, 128.1, 128.0, 127.9,
127.7, 98.1, 81.6, 81.5, 80.1, 75.8, 75.4, 73.5, 69.3, 55.5, 7.7; HRMS (ESI) calcd for
[C28H31IO5 + Na]+ 597.1108, found 597.1127. The data are in accordance with reported
values.32
2,3,4-Tri-O-benzyl-5,6-dideoxy-D-xylo-hex-5-enose (9)
To a solution of 14 (5.0 g, 8.7 mmol) in THF/H2O (200 mL/22 mL) was added pre-activated
Zn (5.7 g, 87 mmol). The reaction mixture was sonicated at 40 °C until full conversion was
observed by TLC. After cooling the reaction mixture to room temperature, Et2O (340 mL)
and H2O (130 mL) were added. The resulting mixture was filtered, and the organic layer
was separated. The organic layer was washed with H2O (150 mL) and brine (150 mL), dried
over anhydrous K2CO3, and evaporated under reduced pressure. The resulting yellow syrup
was purified by silica column chromatography (EtOAc:hexanes 1:9 and 1:5) to afford 9 as a
colorless oil (3.4 g, 93%). 1H NMR (400 MHz, CDCl3) δ 9.65 (s, 1H), 7.36–7.23 (m, 15H),
5.83 (ddd, J = 16.8, 10.8, 7.7 Hz, 1H), 5.28 (d, J = 10.2 Hz, 1H), 5.27 (d, J = 17.6 Hz, 1H),
4.71 (d, J = 11.8 Hz, 2H), 4.58 (d, J = 11.7 Hz, 1H), 4.54 (d, J = 11.5 Hz, 1H), 4.49 (d, J =
11.8 Hz, 1H), 4.36 (d, J = 11.5 Hz, 1H), 4.15 (dd, J = 7.5, 5.1 Hz, 1H), 3.87 (d, J = 4.4 Hz,
1H), 3.80 (t, J = 4.7 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 201.6, 137.8, 137.7, 137.2,
134.8, 128.5, 128.4, 128.3, 128.2, 128.1, 127.9, 127.6, 119.4, 82.4, 81.8, 79.9, 74.5, 73.3,
70.9; HRMS (ESI) calcd for [C27H28O4 + K]+ 455.1619, found 455.1837. The data are in
accordance with reported values.33
(2S,3S,4R)-N-Allyl-2,3,4-tris(benzyloxy)hex-5-en-1-amine (15)
To a solution of 9 (3.9 g, 9.3 mmol) and allylamine (0.53 g, 9.3 mmol) in 1,2-dichloroethane
(40 mL) was added NaBH(OAc)3 (2.7 g, 13 mmol). The reaction mixture was stirred at
room temperature for 16 h and quenched by adding aqueous saturated NaHCO3 (100 mL).
The mixture was extracted with EtOAc (300 mL) and the organic layer was washed with
aqueous saturated NaHCO3 (100 mL). The organic layer was dried over anhydrous MgSO4
and concentrated under reduced pressure. The crude product was purified by silica column
chromatography (MeOH:CH2Cl2 1:19) to give 15 as a pale yellow oil (3.6 g, 86%):
 (c 1.00 CHCl3); IR (neat) 3329, 3064, 3030, 2866, 1642, 1497, 1454, 1351,
1208, 1088, 1068, 995, 922, 735, 687 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.37–7.21 (m,
15H), 5.88 (m, 1H), 5.77 (m, 1H), 5.29 (d, J = 15.4 Hz, 1H), 5.26 (d, J = 12.4 Hz, 1H), 5.07
(dd, J = 17.2, 1.7 Hz, 1H), 5.02 (dd, J = 10.2, 1.4 Hz, 1H), 4.74 (s, 2H), 4.64 (d, J = 11.5 Hz,
1H), 4.63 (d, J = 11.8 Hz, 1H), 4.58 (d, J = 11.5 Hz, 1H), 4.36 (d, J = 11.8 Hz, 1H), 4.03 (dd,
J = 7.4, 5.0 Hz, 1H), 3.77 (q, J = 5.6 Hz, 1H), 3.61 (t, J = 5.3 Hz, 1H), 3.05 (m, 2H), 2.70
(dd, J = 12.3, 4.7 Hz, 1H), 2.58 (dd, J = 12.3, 6.5 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ
138.8, 138.6, 138.3, 136.9, 135.6, 128.4, 128.3, 128.2, 128.1,127.9, 127.6, 127.5, 118.6,
115.7, 82.0, 80.6, 79.3, 74.9, 73.1, 70.5, 52.4, 49.0; HRMS (ESI) calcd for [C30H35NO3 +
H]+ 458.2690, found 458.2690.
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A solution of amine 15 (3.5 g, 7.7 mmol), tosyl chloride (1.8 g, 9.3 mmol), DMAP (0.094 g,
0.77 mmol) and triethylamine (1.6 g, 15 mmol) in CH2Cl2 (35 mL) was stirred at room
temperature for 3 h. The reaction mixture was then washed with H2O (3x 35 mL) and the
combined water layer was back-extracted with CH2Cl2 (2 × 35 mL). The combined organic
layer was dried over anhydrous MgSO4 and concentrated under reduced pressure. The
residue was purified by silica column chromatography (EtOAc:hexanes 1:9) to give
sulfonamide 8a as a colorless oil (4.0 g, 84%).  (c 1.00 CHCl3); IR (neat) 3064,
3030, 2868, 1598, 1496, 1454, 1345, 1160, 1090, 930, 736, 698 cm−1; 1H NMR (400 MHz,
CDCl3) δ 7.59 (d, J = 8.1 Hz, 2H), 7.35–7.23 (m, 15H), 7.20 (d, J = 8.1 Hz, 2H), 5.84 (ddd,
J = 17.3, 10.4, 7.7 Hz, 1H), 5.45 (m, 1H), 5.27 (dd, J = 10.4, 1.6 Hz, 1H), 5.22 (ddd, J =
17.3, 1.6, 0.9 Hz, 1H), 4.99 (dd, J = 3.8, 1.4 Hz, 1H), 4.96 (dd, J = 10.4, 1.4 Hz, 1H), 4.76
(d, J = 11.6 Hz, 1H), 4.69 (d, J = 11.6 Hz, 1H), 4.61 (d, J = 11.6 Hz, 1H), 4.59 (d, J = 11.7
Hz, 1H), 4.55 (d, J = 11.6 Hz, 1H), 4.36 (d, J = 11.7 Hz, 1H), 4.14 (dd, J = 7.7, 5.3 Hz, 1H),
3.99 (dt, J = 7.7, 4.3 Hz, 1H), 3.81(dd, J = 6.4, 1.3 Hz, 2H), 3.56 (t, J = 4.9 Hz, 1H), 3.43
(dd, J = 14.9, 4.2 Hz, 1H), 3.22 (dd, J = 14.9, 7.6 Hz, 1H), 2.40 (s, 3H)); 13C NMR (100
MHz, CDCl3) δ 143.1, 138.5, 138.3, 136.8,135.5, 132.9, 129.6, 128.3, 128.2, 128.0, 127.9,
127.6, 127.5, 127.4, 118.8, 80.7, 80.5, 78.5, 74.1, 73.3, 70.6, 52.5, 48.4, 21.5; HRMS (ESI)
calcd for [C37H41NO5S + Na]+ 634.2598, found 634.2600.
(3S,4S,5R,Z)-3,4,5-Tris(benzyloxy)-1-tosyl-1,2,3,4,5,8-hexahydroazocine (7a)
A solution of 8a (3.9 g, 6.3 mmol) and Grubbs catalyst II (0.53 g, 0.63 mmol, 10 mol%) in
CH2Cl2 (1600 mL) was refluxed for 1 h. The reaction mixture was concentrated under
reduced pressure and the resulting crude product was purified by silica column
chromatography (EtOAc:hexanes 1:5) affording 7a as a viscous semisolid (3.1 g, 84%).
 (c 1.00 CHCl3); IR (neat) 3063, 3029, 2865, 1453, 1347, 1162, 1092, 1070, 738,
698 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.58 (d, J = 8.3 Hz, 2H), 7.35–7.22 (m, 17H), 5.67
(ddd, J = 11.8, 6.5, 1.7 Hz, 1H), 5.45 (br d, J = 11.8 Hz, 1H), 5.00 (t, J = 7.6 Hz, 1H), 4.91
(d, J = 11.1 Hz, 1H), 4.70 (d, J = 11.7 Hz, 1H), 4.66 (d, J = 11.1 Hz, 1H), 4.62 (s, 2H), 4.58
(d, J = 11.7 Hz, 1H), 4.22 (br d, J = 16.4 Hz, 1H), 3,96 (ddd, J = 8.5, 6.8, 3.3 Hz, 1H), 3.60
(dd, J = 14.5, 3.3 Hz, 1H), 3.57 (dd, J = 9.1, 6.8 Hz, 1H), 3.24 (dd, J = 16.4, 4.9 Hz, 1H),
2.87 (dd, J = 14.5, 8.5 Hz, 1H), 2.4 (s, 3H)); 13C NMR (100 MHz, CDCl3) δ 143.7, 138.9,
138.7, 138.6, 134.2, 134.0, 129.8, 128.4, 128.3, 128.0, 127.8, 127.6, 127.5, 127.4, 125.0,
83.5, 81.4, 77.6, 75.3, 73.2, 72.5, 48.9, 48.0, 21.6; HRMS (ESI) calcd for [C35H37NO5S +
Na]+ 606.2285, found 606.2277.
tert-Butyl Allyl((2S,3S,4R)-2,3,4-tris(benzyloxy)hex-5-en-1-yl)carbamate (8b)
To a solution of 15 (1.6 g, 3.5 mmol) and Boc anhydride (916 mg, 4.20 mmol) in CH2Cl2
(14 mL) was added DMAP (43 mg, 0.35 mmol). The mixture was stirred at room
temperature for 16 h and then concentrated under reduced pressure. The residue was purified
by column chromatography (EtOAc:hexanes 1:8) to give 8b (1.56 g, 80%) as a colorless oil.
 (c 1.00 CHCl3); IR (neat) 3065, 3031, 2977, 1694, 1644, 1455, 1405, 1247, 925,
735 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.35–7.22 (m, 15H), 5.81 (m, 1H), 5.68 (br s, 1H),
5.27 (d, J = 10.8 Hz, 1H), 5.22 (d, J = 17.8 Hz, 1H), 5.04 (d, J = 9.6 Hz, 1H), 4.96 (d, J =
17.1 Hz, 1H), 4.82 (d, J = 11.5 Hz, 1H), 4.67 (d, J = 11.5 Hz, 1H), 4.60 (m, 2H), 4.38 (d, J =
11.8 Hz, 1H), 4.14 (t, J = 6.9 Hz, 1H), 3.91 (dd, J = 9.4, 5.2 Hz, 1H), 3.71 (br s, 2H), 3.48
(dd, J = 6.0, 4.3 Hz, 1H), 3.37 (br s, 2H), 1.44 (s, 9H); 13C NMR (100 MHz, CDCl3) δ
155.6, 138.5, 135.5, 134.0, 128.3, 128.2, 128.0, 127.5, 118.9, 115.9, 81.2, 79.6, 74.2, 73.3,
70.7, 50.9, 47.8, 28.5; HRMS (ESI) calcd for [C35H43NO5 + H]+ 558.3219, found 558.3229.
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A solution of 8b (100 mg, 0.179 mmol) and Grubbs catalyst II (15 mg, 0.018 mmol, 10 mol
%) in CH2Cl2 (45 mL) was refluxed for 4 h. The reaction mixture was concentrated under
reduced pressure and the resulting crude product was purified by silica column
chromatography (EtOAc:hexaness 1:8) affording 88 mg (92%) of a rotameric mixture of 7b
(1:1.4) as a colorless oil. Rotamer A: 1H NMR (400 MHz, CDCl3) δ 7.36–7.23 (m, 15H),
5.66 (m, 2H), 4.84 (d, J = 12.0 Hz, 1H), 4.71–4.50 (m, 5H), 4.47 (m, 1H), 4.17 (d, J = 16.1
Hz, 1H), 3.90 (dd, J = 14.6, 3.0 Hz, 1H), 3.80 (m, 1H), 3.66 (dd, J = 16.6, 4.0 Hz, 1H), 3.60
(dd, J = 9.0, 6.5 Hz, 1H), 3.25 (dd, J = 14.3, 8.3 Hz, 1H), 1.42 (s, 9H); 13C NMR (100 MHz,
CDCl3) δ 155.3, 138.7, 138.5, 133.0, 132.8, 128.4, 128.3, 128.2, 127.7, 127.6, 127.5, 127.4,
127.3, 83.8, 79.9, 79.8, 77.5, 75.1, 72.7, 71.9, 46.6, 45.8, 28.4. Rotamer B: 1H NMR (400
MHz, CDCl3) δ 7.36–7.23 (m, 15H), 5.66 (m, 2H), 4.89 (d, J = 11.0 Hz, 1H), 4.71–4.50 (m,
5H), 4.47 (m, 2H), 3.90 (dd, J = 14.6, 3.0 Hz, 1H), 3.80 (m, 1H), 3.60 (dd, J = 9.0, 6.5 Hz,
1H), 3.57 (dd, J = 18.7, 2.6 Hz, 1H), 3.16 (dd, J = 14.7, 8.4 Hz, 1H), 1.46 (s, 9H); 13C NMR
(100 MHz, CDCl3) δ 155.5, 138.9, 138.6, 133.0, 132.8, 128.4, 128.3, 128.2, 127.7, 127.6,
127.5, 127.4, 127.3, 83.6, 80.7, 80.5, 77.5, 75.4, 72.9, 71.9, 46.6, 46.5, 28.5. HRMS (ESI)
calcd for [C33H39NO5 + Na]+ 552.2720, found 552.2711.
(3S,4S,5R,Z)-3,4,5-Tris(benzyloxy)-1,2,3,4,5,8-hexahydroazocine (16)
A solution of Na metal (405 mg, 17.6 mmol) and naphthalene (2.48 g, 19.4 mmol) in 1,2-
dimethoxyethane (18 mL) was stirred at room temperature for 2 h. To a solution of 7a (664
mg, 1.14 mmol) in 1,2-dimethoxyethane (13 mL) at −78 °C was added the Na-naphthalene
solution (11.4 mL) dropwise for 30 min. The reaction mixture was stirred at −78 °C for 5
min and then H2O (2.1 mL) was slowly added to the mixture at −78 °C to quench the
reaction. The reaction mixture was diluted with Et2O (120 mL), dried over anhydrous
MgSO4 and concentrated under reduced pressure. The residue was purified by silica column
chromatography (MeOH:CH2Cl2 1: 9) to furnish 16 as a yellowish oil (366 mg, 75%).
 (c 1.00 CHCl3); IR (neat) 3364, 3063, 3029, 2863, 1496, 1454, 1355, 1207,
1090, 1069, 735, 697 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.37–7.22 (m, 15H), 5.76 (m,
1H), 5.69 (dd, J = 11.7, 6.7 Hz, 1H), 4.77 (m, 1H), 4.74 (d, J = 11.5 Hz, 1H), 4.65 (d, J =
11.5 Hz, 1H), 4.63 (d, J = 11.8 Hz, 1H), 4.59 (d, J = 11.8 Hz, 1H), 4.53 (d, J = 11.8 Hz, 1H),
4.49 (d, J = 11.8 Hz, 1H), 3.71 (dd, J = 7.4, 5.4 Hz, 1H), 3.57 (m, 1H), 3.44 (dd, J = 16.8,
4.8 Hz, 1H), 3.29 (ddd, J = 16.8, 5.2, 1.5 Hz, 1H), 3.06 (m, 2H)); 13C NMR (100 MHz,
CDCl3) δ 138.7,138.6, 138.5, 132.9, 130.0, 128.4, 128.3, 128.1, 127.7, 127.6, 127.5, 84.0,
79.9, 78.2, 74.2, 72.3, 71.7, 48.1, 47.8; HRMS (ESI) calcd for [C28H31NO3 + Na]+
452.2196, found 452.2209. Compound 16 was also obtained from 7b. Compound 7b (20
mg, 0.038 mmol) was dissolved with 4N-HCl in dioxane (118 µL, 0.47 mmol). The solution
was stirred at room temperature for 1 h. Excess HCl and dioxane were removed by
evaporation. Conc. NH4OH (60 µL) and H2O (300 µL) were added to the concentrated
mixture. The mixture was extracted with CH2Cl2 (3×2 mL), dried over anhydrous MgSO4
and concentrated under reduced pressure. The crude product was purified by silica column
chromatography (MeOH: CH2Cl2 1:9) to give 16 as a yellowish oil (14 mg, 85%). All the
spectra are identical with the ones of compound 16 obtained from compound 7a.
(3S,4S,5R,Z)-3,4,5-Tris(benzyloxy)-1-butyl-1,2,3,4,5,8-hexahydroazocine (17a)
To a solution of 16 (200 mg, 0.47 mmol) and butyraldehyde (40 µL, 0.45 mmol) in 1,2-
dichloroethane (2 mL) at room temperature was added NaBH(OAc)3 (140 mg, 0.65 mmol).
The reaction mixture was stirred at room temperature for 16 h, diluted with EtOAc (16 mL),
washed with saturated NaHCO3 (2 × 4 mL), dried over anhydrous MgSO4 and concentrated
under reduced pressure. The crude product was purified by silica column chromatography
(EtOAc:hexanes 1:3) to give 17a as a yellowish oil (170 mg, 75%).  (c 1.0 CHCl3);
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IR (neat) 3063, 3029, 2930, 2861, 1496, 1454, 1358, 1207, 1091, 1068, 734, 697 cm−1; 1H
NMR (400 MHz, CDCl3) δ 7.36–7.22 (m, 15H), 5.57 (ddd, J = 11.9, 5.7, 1.6 Hz, 1H), 5.50
(br d, J = 11.7 Hz, 1H), 5.18 (br s, 1H), 4.94 (d, J = 10.7 Hz, 1H), 4.69 (d, J = 11.3 Hz, 1H),
4.68 (d, J = 10.7 Hz, 1H), 4.66 (d, J = 11.3 Hz, 1H), 4.59 (d, J = 11.6 Hz, 1H), 4.58 (d, J =
11.6 Hz, 1H), 3.54 (m, 2H), 3.25 (br d, J = 16.4 Hz, 1H), 2.97 (dd, J = 16.4, 3.6 Hz, 1H),
2.76 (dd, J = 13.8, 8.9 Hz, 1H), 2.57 (d, J = 13.8 Hz, 1H), 2.37 (m, 2H), 1.35 (m, 2H), 1.24
(sex, J = 7.2 Hz, 2H), 0.86 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 139.3, 139.2,
138.9, 133.1, 128.8, 128.3, 128.2, 127.9, 127.7, 127.5, 127.4, 127.2, 85.1, 81.4, 78.2, 75.7,
72.9, 71.9, 57.7, 55.1, 55.0, 30.0, 20.5, 14.0; HRMS (ESI) calcd for [C32H39NO3 + H]+
486.3003, found 486.3020.
(3S,4S,5R,Z)-3,4,5-Tris(benzyloxy)-1-nonyl-1,2,3,4,5,8-hexahydroazocine (17b)
To a solution of 16 (220 mg, 0.51 mmol) and nonyl aldehyde (85 µL, 0.49 mmol) in 1,2-
dichloroethane (2 mL) at room temperature was added NaBH(OAc)3 (152 mg, 0.717 mmol).
The reaction mixture was stirred at room temperature for 16 h, diluted with EtOAc (18 mL),
washed with saturated NaHCO3 (2 × 5 mL), dried over anhydrous MgSO4 and concentrated
under reduced pressure. The crude product was purified by silica column chromatography
(EtOAc:hexanes 1:4) to give 17b as a yellowish oil (217 mg, 76%).  (c 1.0
CHCl3); IR (neat) 3063, 3030, 2926, 2855, 1496, 1454, 1357, 1207, 1092, 1068, 733, 697
cm−1; 1H NMR (400 MHz, CDCl3) δ 7.38–7.22 (m, 15H), 5.57 (dd, J = 11.5, 5.5 Hz, 1H),
5.50 (br d, J = 11.8 Hz, 1H), 5.18 (br s, 1H), 4.94 (d, J = 10.7 Hz, 1H), 4.69 (d, J = 11.4 Hz,
1H), 4.68 (d, J = 10.7 Hz, 1H), 4.65 (d, J = 11.4 Hz, 1H), 4.59 (d, J = 11.6 Hz, 1H), 4.58 (d,
J = 11.6 Hz, 1H), 3.53 (m, 2H), 3.25 (br d, J = 16.4 Hz, 1H), 2.97 (dd, J = 16.5, 3.8 Hz, 1H),
2.76 (dd, J = 13.9, 8.9 Hz, 1H), 2.58 (d, J = 13.9 Hz, 1H), 2.37 (m, 2H), 1.42–1.15 (br m,
14H), 0.87 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 139.2, 138.8, 133.1, 128.7,
128.3, 128.2, 127.8, 127.7, 127.5, 127.4, 127.2, 85.1, 81.4, 78.3, 75.6, 72.9,?72.0, 58.0, 55.1,
54.9, 31.9, 29.6, 29.3, 27.8, 27.4, 22.7, 14.1; HRMS (ESI) calcd for [C37H49NO3 + H]+
556.3785, found 556.3804.
(3S,4S,5R)-1-Butylazocane-3,4,5-triol (1)
To a solution of 17a (80 mg, 0.17 mmol) in MeOH (5 mL) was added PdCl2 (20 mg, 0.12
mmol). The reaction mixture was stirred under H2 atmosphere at room temperature for 16 h.
The reaction mixture was filtered through Celite and concentrated under reduced pressure.
The residue was purified by SPE-amine column chromatography (MeOH:CH2Cl2 1:100 to
1:50 gradient) to furnish 1 as a colorless thick oil (27 mg, 76%).  (c 1.04 MeOH);
IR (neat) 3363, 2929, 2863, 1653, 1456, 1364, 1102, 1035, 943 cm−1; 1H NMR (400 MHz,
CD3OD) δ 3.89 (dd, J = 8.4, 3.3 Hz, 1H), 3.72 (td, J = 9.6, 5.8 Hz, 1H), 3.44 (dd, J = 9.1, 3.3
Hz, 1H), 2.66–2.45 (m, 6H), 1.92–1.74 (m, 3H), 1.59 (m, 1H), 1.50 (quin, J = 7.4 Hz, 2H),
1.36 (m, 2H), 0.95 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, CD3OD) δ 80.6, 71.9, 71.8,
60.1, 60.0, 53.7, 30.8, 27.8, 25.9, 21.6, 14.3; HRMS (ESI) calcd for [C11H23NO3 + H]+
218.1751, found 218.1753.
(3S,4S,5R)-1-Nonylazocane-3,4,5-triol (2)
To a solution of 17b (70 mg, 0.13 mmol) in MeOH (4 mL) was added PdCl2 (16 mg, 0.088
mmol). The reaction mixture was stirred under H2 atmosphere at room temperature for 16 h.
The reaction mixture was filtered through Celite and concentrated under reduced pressure.
The residue was purified by SPE-amine column chromatography (MeOH:CH2Cl2 1:100 to
1:50 gradient) to furnish 2 as a colorless thick oil (28 mg, 78%).  (c 1.03 MeOH);
IR (neat) 3392, 2923, 2854, 1647, 1468, 1364, 1105, 1039, 950 cm−1 ; 1H NMR (400 MHz,
CD3OD) δ 3.79 (dd, J = 8.2, 3.3 Hz, 1H), 3.62 (td, J = 9.6, 5.7 Hz, 1H), 3.34 (dd, J = 9.0, 3.3
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Hz, 1H), 2.56–2.35 (m, 6H), 1.82–1.64 (m, 3H), 1.49 (m, 1H), 1.42 (m, 2H), 1.23 (br s,
12H), 0.81 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CD3OD) δ 80.6, 72.0, 71.8, 60.5, 60.0,
53.8, 33.0, 30.6, 30.4, 28.6, 28.4, 27.9, 25.9, 23.7, 14.4; HRMS (ESI) calcd for [C16H33NO3
+ H]+ 288.2533, found 288.2535.
(3S,4S,5R,Z)-1-Butyl-1,2,3,4,5,8-hexahydroazocine-3,4,5-triol (3)
To liquid ammonia (24 mL) at −78 °C was added granular Li metal (91 mg, 13 mmol). The
solution was stirred at −78 °C for 20 min. A solution of 17a (80 mg, 0.16 mmol) in THF (4
mL) was added slowly to the Li-ammonia solution at −78 °C and then the reaction mixture
was stirred at −78 °C for 1 h. Liquid ammonia was removed by nitrogen purge at −78 °C.
When most ammonia was removed, MeOH (30 mL) containing 4 drops of H2O was added
to the residue at −78 °C to quench the reaction. After stirring at −78 °C for 20 min, the
mixture was evaporated under reduced pressure. The residue was dissolved in MeOH/
CH2Cl2 (2:8, 5 mL) and filtered through Celite. The filtered solution was concentrated in
vacuo and purified by SPE-amine column chromatography (MeOH:CH2Cl2 0.5:100 to 4:100
gradient) to furnish 3 as a colorless thick oil (21 mg, 59%).  (c 1.04 MeOH); IR
(neat) 3370, 3020, 2957, 2932, 2871, 1655, 1458, 1377, 1039, 968, 725 cm−1; 1H NMR (400
MHz, CD3OD) δ 5.86 (m, 1H), 5.71 (dt, J = 12.2, 3.5 Hz, 1H), 4.18 (br s, 1H), 3.71 (m, 1H),
3.46 (dd, J = 8.5, 3.7 Hz, 1H), 3.38 (br d, J = 17.5 Hz, 1H), 3.04 (br d, J = 18.5 Hz, 1H), 2.81
(t, J = 11.6 Hz, 1H), 2.54 (m, 3H), 1.52 (quin, J = 7.5 Hz, 2H), 1.36 (sex, J = 7.4 Hz, 2H),
0.95 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, CD3OD) δ 132.9, 130.3, 80.7, 72.3, 70.9,
60.9, 59.3, 56.5, 30.3, 21.6, 14.2; HRMS (ESI) calcd for [C11H21NO3 + Na]+ 238.1414,
found 238.1423.
(3S,4S,5R,Z)-1-Nonyl-1,2,3,4,5,8-hexahydroazocine-3,4,5-triol (4)
To liquid ammonia (21 mL) at −78 °C was added granular Li metal (80 mg, 12 mmol). The
solution was stirred at −78 °C for 20 min. A solution of 17b (80 mg, 0.14 mmol) in THF (4
mL) was added slowly to the Li-ammonia solution at −78 °C and then the reaction mixture
was stirred at −78 °C for 1 h. Liquid ammonia was removed by nitrogen purge at −78 °C.
When most ammonia was removed, MeOH (30 mL) containing 5 drops of H2O was added
to the residue at −78 °C to quench the reaction. After stirring at −78 °C for 20 min, the
mixture was evaporated under reduced pressure. The residue was dissolved in MeOH/
CH2Cl2 (1:9, 5 mL) and filtered through Celite. The filtered solution was concentrated in
vacuo and purified by SPE-amine column chromatography (MeOH:CH2Cl2 0.5:100 to 4:100
gradient) to furnish 4 as a semisolid (27 mg, 66%).  (c 1.05 MeOH); IR (neat)
3408, 3226, 2921, 2853, 1660, 1486, 1459, 1360, 1294, 1074, 1039, 974, 715 cm−1 ; 1H
NMR (400 MHz, CD3OD) δ 5.77 (m, 1H), 5.61 (dt, J = 12.3, 3.5 Hz, 1H), 4.08 (br s, 1H),
3.61 (m, 1H), 3.36 (dd, J = 8.4, 3.7 Hz, 1H), 3.28 (br d, J = 18.1 Hz, 1H), 2.94 (br d, J = 18.5
Hz, 1H), 2.71 (t, J = 11.6 Hz, 1H), 2.44 (m, 3H), 1.44 (br t, J = 6.9 Hz, 2H), 1.23 (br s,12H),
0.81 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CD3OD) δ 133.0, 130.3, 80.7, 72.3, 70.9,
60.9, 59.7, 56.6, 33.0, 30.6, 30.4, 28.4, 28.1, 23.7, 14.4; HRMS (ESI) calcd for [C16H31NO3
+ Na]+ 308.2196, found 308.2194.
(3R,4R,5R,6R,7S)-5,6,7-Tris(benzyloxy)-1-tosylazocane-3,4-diol (18)
To a solution of 7a (300 mg, 0.514 mmol) in THF/ t-BuOH/ H2O (3 mL/9 mL/9 mL) were
added K2CO3 (213 mg, 1.54 mmol), K3(FeCN)6 (508 mg, 1.54 mmol), (DHQ)2-PHAL (40
mg, 0.051 mmol). The mixture was stirred at 0 °C for 5 min and then to the solution were
added CH3SO2NH2 (98 mg, 1.0 mmol) and K2OsO2(OH)4 (4 mg, 0.01 mmol). After the
reaction mixture had been stirred at room temperature for 40 h, Na2SO3 (780 mg, 6.2 mmol)
was added for quenching and the mixture was stirred for 40 min. The mixture was diluted
with H2O (25 mL) and extracted with EtOAc (4 × 75 mL). The organic layer was washed
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with 2N-KOH (120 mL), dried over anhydrous MgSO4 and concentrated under reduced
pressure. The residue was purified by silica column chromatography (EtOAc:hexanes 1:1) to
give 18 as a white foam (260 mg, 82%).  (c 1.00 MeOH); IR (neat) 3392, 3063,
3030, 2924, 1598, 1496, 1454, 1344, 1160, 1089, 1072, 908, 816, 726, 699 cm−1; 1H NMR
(400 MHz, CDCl3) δ 7.66 (d, J = 8.3 Hz, 2H), 7.37–7.23 (m, 15H), 7.16 (m, 2H), 4.78 (d, J
= 11.8 Hz, 1H), 4.68 (d, J = 11.1 Hz, 1H), 4.62 (d, J = 11.1 Hz, 1H), 4.56 (d, J = 11.8 Hz,
1H), 4.44 (d, J = 11.1 Hz, 1H), 4.38 (d, J = 11.1 Hz, 1H), 4.38 (d, J = 8.0 Hz, 1H), 4.16–4.01
(m, 3H), 3.99–3.91 (m, 2H), 3.68 (q, J = 4.0 Hz, 1H), 3.39 (dd, J = 14.8, 5.0 Hz, 1H), 2.96
(dd, J = 14.8, 10.7 Hz, 1H), 2.82 (dd, J = 13.8, 3.0 Hz, 1H), 2.67 (d, J = 9.0 Hz, 1H), 2.43 (s,
3H); 13C NMR (100 MHz, CDCl3) δ 143.8, 138.3, 138.0, 135.7, 134.1, 129.8, 128.8, 128.6,
128.4, 128.3, 128.0, 127.8, 127.7, 127.5, 83.8, 80.7, 79.4, 74.9, 74.6, 73.8, 73.6, 71.8, 48.2,
47.4, 21.6; HRMS (ESI) calcd for [C35H39NO7S + Na]+ 640.2345, found 640.2348.
(3S,4R,5S,6R,7R)-3,4,5,6,7-Pentakis(benzyloxy)-1-tosylazocane (19)
To a solution of 18 (700 mg, 1.1 mmol) in dry DMF (4.2 mL) at 0 °C were added sodium
hydride (60% dispersion in mineral oil, 159 mg, 3.97 mmol) and benzyl bromide (582 mg,
3.40 mmol). The reaction mixture was stirred at room temperature for 15 h and then
quenched with MeOH (20 drops). The reaction mixture was diluted with H2O (42 mL) and
extracted with EtOAc (4 × 80 mL). The organic layer was washed with H2O (160 mL) and
brine (2 × 160 mL), dried over anhydrous MgSO4, and concentrated under reduced pressure.
The crude product was purified by silica column chromatography (EtOAc:hexanes 1:5) to
afford 19 as a colorless thick oil (787 mg, 87%).  (c 1.00 CHCl3); IR (neat) 3063,
3030, 2930, 2869, 1598, 1496, 1454, 1346, 1161, 1089, 912, 816, 737, 698 cm−1; 1H NMR
(400 MHz, CDCl3) δ 7.52 (d, J = 8.3 Hz, 2H), 7.37–7.19 (m, 27H), 4.91 (d, J = 10.6 Hz,
1H), 4.82 (d, J = 11.5 Hz, 1H), 4.81 (d, J = 11.8 Hz, 1H), 4.79 (d, J = 11.9 Hz, 1H), 4.75 (d,
J = 10.6 Hz, 1H), 4.74 (d, J = 11.5 Hz, 1H), 4.71 (d, J = 11.8 Hz, 1H), 4.47 (d, J = 11.9 Hz,
1H), 4.33 (d, J = 11.8 Hz, 1H), 4.28 (d, J = 11.8 Hz, 1H), 4.22 (s, 1H), 4.01 (m, 2H), 3.82 (d,
J = 8.1 Hz, 1H), 3.60 (dd, J = 13.8, 5.0 Hz, 1H), 3.49–3.41 (m, 2H), 3.11 (dd, J = 15.1, 10.1
Hz, 1H), 2.82 (dd, J = 13.8, 10.7 Hz, 1H), 2.40 (s, 3H); 13C NMR (100 MHz, CDCl3) δ
143.7, 139.2, 139.0, 138.9, 138.2, 134.8, 129.8, 128.4, 128.3, 128.2, 128.0, 127.9, 127.7,
127.6, 127.5, 127.3, 127.2, 83.9, 83.8, 83.2, 81.8, 81.6, 76.2, 74.7, 74.2, 73.8, 71.9, 51.8,
50.2, 21.5; HRMS (ESI) calcd for [C49H51NO7S + Na]+ 820.3278, found 820.3307.
(3S,4R,5S,6R,7R)-3,4,5,6,7-Pentakis(benzyloxy)azocane (20)
A solution of Na metal (583 mg, 25.4 mmol) and naphthalene (3.58 g, 27.9 mmol) in 1,2-
dimethoxyethane (25 mL) was stirred at room temperature for 2 h. To a solution of 19 (763
mg, 0.956 mmol) in 1,2-dimethoxyethane (11 mL) at −78 °C was added the Na-naphthalene
solution (3.8 mL) dropwise for 20 min. After the reaction mixture was stirred at −78 °C for
10 min, H2O (1.5 mL) with Et2O (10 mL) and 1,2-dimethoxyethane (2 mL) was slowly
added to the mixture at −78 °C to quench the reaction. The slurry was stirred at −78 °C until
the green color disappeared. The reaction mixture was diluted with Et2O (120 mL), dried
over anhydrous MgSO4 and concentrated under reduced pressure. The residue was purified
by silica column chromatography (MeOH:CH2Cl2 1: 13) to furnish 20 as a yellowish oil
(440 mg, 72%).  (c 1.0 CHCl3); IR (neat) 3384, 3063, 3030, 2868, 1496, 1454,
1362, 1208, 1092, 1072, 736 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.42–7.20 (m, 25H),
4.85–4.67 (m, 6H), 4.60 (d, J = 11.6 Hz, 1H), 4.58 (d, J = 11.6 Hz, 1H), 4.39 (d, J = 12.0 Hz,
1H), 4.34 (d, J = 12.0 Hz, 1H), 4.09 (br s, 1H), 3.96 (t, J = 8.1 Hz, 1H), 3.84 (d, J = 7.8 Hz,
1H), 3.44–3.36 (m, 2H), 3.09–2.99 (m, 2H), 2.92 (dd, J = 14.6, 10.1 Hz, 1H), 2.85 (dd, J =
13.9, 4.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 139.1, 139.0, 138.9,138.7, 138.6, 128.3,
128.2, 128.0,127.8, 127.6, 127.5, 127.4, 83.5, 83.3, 82.7, 82.2, 81.6, 75.5, 74.3, 73.5, 73.4,
71.5, 50.0, 48.3; HRMS (ESI) calcd for [C42H45NO5 + H]+ 644.3370, found 644.3386.
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To a solution of 20 (204 mg, 0.317 mmol) and butyraldehyde (27 µL, 0.30 mmol) in 1,2-
dichloroethane (1.5 mL) at room temperature was added NaBH(OAc)3 (94 mg, 0.44 mmol).
The reaction mixture was stirred at room temperature for 16 h, diluted with EtOAc (30 mL)
and washed with saturated NaHCO3 (2×10 mL). The organic layer was dried over
anhydrous MgSO4 and concentrated under reduced pressure. The crude product was purified
by silica column chromatography (first purification EtOAc:hexanes 1:1, second purification
MeOH:CH2Cl2 1:18) to give 21a as a yellowish oil (175 mg, 79%).  (c 1.00
CHCl3); IR (neat) 3063, 3030, 2930, 2862, 1679, 1496, 1454, 1360, 1206, 1072, 735, 698
cm−1; 1H NMR (400 MHz, CDCl3) δ 7.43–7.20 (m, 25H), 4.94 (d, J = 10.3 Hz, 1H), 4.88
(d, J = 12.1 Hz, 1H), 4.81 (d, J = 12.1 Hz, 1H), 4.79 (d, J = 12.1 Hz, 1H), 4.74 (d, J = 10.3
Hz, 1H), 4.70 (d, J = 11.6 Hz, 1H), 4.57 (d, J = 11.6 Hz, 1H), 4.49 (d, J = 12.1 Hz, 1H), 4.30
(d, J = 12.1 Hz, 1H), 4.22 (s, 1H), 4.19 (d, J = 12.1 Hz, 1H), 4.09 (t, J = 8.8 Hz, 1H), 3.88 (d,
J = 9.4 Hz, 1H), 3.33 (ddd, J = 10.6, 8.0, 2.8 Hz, 1H), 3.12–3.01 (m, 2H), 2.79 (dd, J = 13.2,
10.8 Hz, 1H), 2.64 (dd, J = 14.7, 3.2 Hz, 1H), 2.59 (dd, J = 13.6, 5.7 Hz, 1H), 2.42 (m, 1H),
2.25 (m, 1H), 1.17 (br m, 4H), 0.83 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ
139.4, 139.1, 138.9, 138.6, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.5, 127.4, 127.3,
84.0, 83.4, 82.3, 81.9, 76.4, 74.2, 74.0, 73.1, 71.1, 57.8, 57.7, 55.1, 30.5, 20.4, 14.1; HRMS
(ESI) calcd for [C46H53NO5 + H]+ 700.3996, found 700.4004.
(3S,4R,5S,6R,7R)-3,4,5,6,7-Pentakis(benzyloxy)-1-nonylazocane (21b)
To a solution of 20 (198 mg, 0.308 mmol) and nonyl aldehyde (51 µL, 0.30 mmol) in 1,2-
dichloroethane (1.5 mL) at room temperature was added NaBH(OAc)3 (91 mg, 0.43 mmol).
The reaction mixture was stirred at room temperature for 16 h, diluted with EtOAc (30 mL)
and washed with saturated NaHCO3 (2×10 mL). The organic layer was dried over
anhydrous MgSO4 and concentrated under reduced pressure. The crude product was purified
by silica column chromatography (first purification EtOAc:hexanes 1:1, second purification
MeOH:CH2Cl2 1:16) to give 21b as a yellowish oil (200 mg, 84%).  (c 1.00
CHCl3); IR (neat) 3063, 3030, 2925, 2854, 1681, 1496, 1454, 1359, 1206, 1067, 912, 733,
696 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.44–7.13 (m, 25H), 4.93 (d, J = 10.3 Hz, 1H),
4.88 (d, J = 12.1 Hz, 1H), 4.81 (d, J = 12.1 Hz, 1H), 4.79 (d, J = 12.0 Hz, 1H), 4.74 (d, J =
10.3 Hz, 1H), 4.70 (d, J = 11.6 Hz, 1H), 4.58 (d, J = 11.6 Hz, 1H), 4.48 (d, J = 12.0 Hz, 1H),
4.29 (d, J = 12.1 Hz, 1H), 4.22 (s, 1H), 4.19 (d, J = 12.1 Hz, 1H), 4.08 (t, J = 8.8 Hz, 1H),
3.88 (d, J = 9.4 Hz, 1H), 3.33 (ddd, J = 10.5, 8.1, 2.6 Hz,1H), 3.14–3.00 (m, 2H), 2.79 (dd, J
= 13.2, 10.8 Hz, 1H), 2.64 (dd, J = 14.7, 2.7 Hz, 1H), 2.60 (dd, J = 13.2, 5.3 Hz, 1H), 2.41
(m, 1H), 2.25 (m, 1H), 1.36–1.07 (br m, 14H), 0.89 (t, J = 6.8 Hz, 3H); 13C NMR (100
MHz, CDCl3) δ 139.4, 139.3, 139.0, 138.8, 138.6, 128.4, 128.3, 128.2, 128.0, 127.9, 127.5,
127.4, 127.3, 83.9, 83.4, 82.3, 82.1, 74.3, 73.9, 73.1, 71.1, 58.1, 57.6, 55.1, 31.9, 29.7, 29.6,
29.4, 28.3, 27.3, 22.7, 14.2; HRMS (ESI) calcd for [C51H63NO5 + H]+ 770.4779, found
770.4770.
(3S,4R,5S,6R,7R)-1-Butylazocane-3,4,5,6,7-pentaol (5)
To a solution of 21a (164 mg, 0.234 mmol) in MeOH (6 mL) was added PdCl2 (33 mg, 0.19
mmol). The reaction mixture was stirred under H2 atmosphere at room temperature for 18 h.
The reaction mixture was filtered through Celite and concentrated under reduced pressure.
The residue was purified by SPE-amine column chromatography (MeOH:CH2Cl2 1:9 and
1:5) to afford 5 as a semisolid (47 mg, 80%).  (c 0.932 MeOH); IR (neat) 3403,
3356, 2947, 2872, 2807, 1683, 1469, 1398, 1105, 1040 cm−1; 1H NMR (400 MHz, CD3OD)
δ 3.89 (m, 3H), 3.63 (td, J = 8.3, 6.1 Hz, 1H), 3.57 (dd, J = 8.5, 4.2 Hz, 1H), 2.84 (dd, J =
14.8, 5.2 Hz, 1H), 2.73 (dd, J = 14.8, 2.7 Hz, 1H), 2.67 (d, J = 6.1 Hz, 1H), 2.67 (d, J = 8.3
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Hz, 1H), 2.59 (t, J = 7.7 Hz, 2H), 1.54 (m, 2H), 1.34 (sex, J = 7.4 Hz, 2H), 0.95 (t, J = 7.3
Hz, 3H); 13C NMR (100 MHz, CD3OD) δ 79.9, 78.6, 74.3, 73.4, 72.6, 60.9, 59.3, 57.1,
30.4, 21.6, 14.3; HRMS (ESI) calcd for [C11H23NO5 + H]+ 250.1649, found 250.1644.
(3S,4R,5S,6R,7R)-1-Nonylazocane-3,4,5,6,7-pentaol (6)
To a solution of 21b (19 mg, 0.025 mmol) in MeOH (0.8 mL) was added PdCl2 (4 mg, 0.02
mmol). The reaction mixture was stirred under H2 atmosphere at room temperature for 18 h.
The reaction mixture was filtered through Celite and concentrated under reduced pressure.
The residue was purified by silica column chromatography (MeOH:CH2Cl2 1:5 and 1:3)
followed by SPE-C18 column chromatography (MeOH:H2O 2:8 to 9:1 gradient) to afford 6
as a semisolid (5.3 mg, 74%).  (c 1.04 MeOH); IR (neat) 3370, 3311, 2921, 2852,
1680, 1467, 1106, 1035 cm−1; 1H NMR (400 MHz, CD3OD) δ 3.90 (m, 3H), 3.62 (td, J =
8.2, 6.0 Hz, 1H), 3.58 (dd, J = 8.4, 4.2 Hz, 1H), 2.84 (dd, J = 14.8, 5.3 Hz, 1H), 2.73 (dd, J =
14.8, 2.7 Hz, 1H), 2.68 (d, J = 6.0 Hz, 1H), 2.67 (d, J = 8.2 Hz, 1H), 2.59 (t, J = 7.7 Hz, 2H),
1.55 (m, 2H), 1.32 (brs, 12H), 0.91 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CD3OD) δ
79.7, 78.3, 73.8, 73.2, 72.4, 61.2, 59.1, 57.0, 33.1, 30.7, 30.6, 30.5, 28.3, 28.0, 23.8, 14.5;
HRMS (ESI) calcd for [C16H33NO5 + H]+ 320.2431, found 320.2428.
(R,E)-3-(2,2-Dimethyl-1,3-dioxolan-4-yl)prop-2-en-1-ol (29)
L-Glyceraldehyde acetonide (28) was obtained from of L-gulono-1,4-lactone as described in
the literature.34,35 The aldehyde 28 (3.07 g, 23.6 mmol) in benzene, was added to a refluxing
solution of (carbethoxymethylene)triphenylphosphorane (12.3 g, 35.4 mmol) in benzene (35
mL) via cannula. The reaction mixture was refluxed overnight and cooled to room
temperature. Benzene was evaporated under reduced pressure and the resulting residue was
triturated with Et2O to separate the insoluble triphenylphosphine oxide. The ether portions
were combined and concentrated. The crude product was then purified by flash silica gel
column chromatography on silica gel using hexanes: EtOAc (9:1) to afford 3.5 g (74%) of
the E-isomer and 0.4 g (8%) of the Z-isomer. To a solution of the E-ester (3.5 g, 17.5 mmol)
in anhydrous CH2Cl2 (100 mL) was added dropwise DIBAL-H (1 M solution in hexanes,
38.5 mmol, 38.5 mL) at −78 °C. The solution was stirred for 1 h at the same temperature and
allowed to warm to 0 °C. After completion of the reaction, (monitored by TLC), methanol
was added slowly (about 2 mL) followed by addition of a cold aqueous saturated potassium
tartrate solution. The biphasic mixture was stirred for 2 h and extracted with EtOAc. The
combined organic extracts were dried over anhydrous sodium sulfate and purified by
column chromatography to give 2.5 g (93%) in 69% overall yield of the allylic alcohol 29 as
a colorless oil.  (c 1.01, MeOH); 1H NMR (400 MHz, CDCl3) δ 5.90 (td, J = 5.0,
15.5 Hz, 1H), 5.67 (dd, J = 7.4, 15.5 Hz, 1H), 4.52 (q, J = 7.1 Hz, 1H), 4.07 (d, J = 6.1 Hz,
3H), 3.85 (s, 1H), 3.57 (t, J = 7.9 Hz, 1H), 1.41 (s, 3H), 1.37 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 133.7, 127.8, 109.3, 76.5, 69.3, 61.9, 26.6, 25.8; HRMS (ESI+, M + Na) m/z calcd
for [C8H14NaO3+] 181.0841, found 181.0839.
(S)-4-((2R,3S)-3-(Benzyloxymethyl)oxiran-2-yl)-2,2-dimethyl-1,3-dioxolane (30)
To a −40 °C suspension of titanium isopropoxide (0.38 mL, 1.30 mmol) and powdered,
activated 3 Å molecular sieves (1 g) in CH2Cl2 (5 mL) was added a solution of (+)-
diisopropyl tartrate (0.303 mL, 1.45 mmol) in CH2Cl2 (2 mL). The mixture was stirred for
40 min at −40 °C, and then a solution of 29 (2.3 g, 15 mmol) in CH2Cl2 (2 mL) was added.
After 1.5 h, cumene hydroperoxide (6.5 mL, 44 mmol) was added dropwise over 3 min. The
resulting solution was stirred for 89 h at −40 °C, then cooled to −78 °C and stirred for 10
min. Bu3P (7.27 mL, 28.0 mmol) was added dropwise over 10 min to quench the reaction.
The mixture was stirred for 30 min, and was then treated with citric acid monohydrate (302
mg, 1.46 mmol) dissolved in acetone-ether (1:9, 21 mL). The cooling bath was removed,
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and the resulting mixture was stirred for an additional 40 min. After filtration through a pad
of Celite, the filtrate was dried over MgSO4, concentrated and purified by silica gel flash
column chromatography (33% EtOAc/hexanes) to furnish 2 g (79%) of the epoxide. To a 0
°C suspension of sodium hydride (0.46 g, 60 % in oil, 12 mmol) in THF (30 mL) was added
a solution of the epoxide (2 g, 11.5 mmol) in THF (40 mL), followed by benzyl bromide
(1.64 mL, 13.8 mmol) and tetrabutylammonium iodide (46 mg, 56.8 m mol). The mixture
was stirred for 8 h at room temperature, and then water (50 mL) was added over 15 min. The
phases were separated and the aqueous phase was further extracted with CH2Cl2. The
combined organic extracts were washed with brine (50 mL), dried over sodium sulfate and
concentrated under reduced pressure. Purification of the crude product by flash silica gel
column chromatography (10% EtOAc/hexanes) provided 2.9 g (96% and 76% yield over
two steps) of benzyl ether 30 as a colorless oil.  (c 1.00, MeOH). 1H NMR (400
MHz, CDCl3) δ 7.26–7.31 (m, 5H), 1.33 (s, 3H), 4.53 (q, J = 6.4 Hz, 2H), 4.04 (t, J = 13.3
Hz, 1H), 3.82–3.89 (m, 2H), 3.77 (dd, J = 2.00, 11.6 Hz, 1H), 3.42 (dd, J = 5.6, 11.6 Hz,
1H), 3.07 (d, J = 2.5 Hz, 1H), 2.93 (d, J = 5.0 Hz, 1H,), 1.41 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 137.8, 128.4, 127.7, 109.9, 75.5, 73.1, 69.4, 66.7, 55.8, 55.2, 26.5, 25.3; HRMS
(ESI) calcd for [C15H20O4 + H]+ 265.1440, found 265.1446.
(S)-4-((1R,2R)-2-Azido-1,3-bis(benzyloxy)propyl)-2,2-dimethyl-1,3-dioxolane (31)
A solution of the epoxy alcohol 30 (2.2 g, 8.3 mmol) in a 2-methoxyethanol: water mixture
(8:l, 94 mL) was refluxed for 5 h with sodium azide, (0.0289 g, 41.6 mmol) and ammonium
chloride (0.019 g, 33 mmol). The reaction mixture was cooled to room temperature,
concentrated under reduced pressure and the crude product was purified by flash silica gel
column chromatography. To a suspension of NaH (0.30 g, 60 % in oil, 7.8 mmol) in THF
(180 mL) was added a solution of the azide derivative (2.26 g, 7.4 mmol) in THF (40 mL),
followed by benzyl bromide (1.00 mL, 0.0944 mmol). The mixture was stirred for 1.5 h at
rt, and then H2O (50 mL) was added over 15 min. The phases were separated and the
aqueous phase was further extracted with Et2O (2×100 mL). The combined organic extracts
were washed with brine (50 mL), dried (MgSO4) and concentrated under reduced pressure.
Purification of the crude product by silica gel flash column chromatography (6% EtOAc/
hexanes) provided 2.6 g (78% yield over two steps) of compound 31 as colorless oil.
 (c 1.00, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.33–7.37 (m, 10H), 4.70 (d t,
J = 12.7 Hz, 6.04 Hz, 2H), 4.60 (d, J = 6.0 Hz, 6.4 Hz 2H), 4.20 (q, J = 6.3 Hz, 1H), 4.05
(dd, J = 6.4, 8.3 Hz, 1H), 3.90 (d, J = 2.2 Hz, 2H), 3.68–3.76 (m, 3H), 1.42 (s, 3H), 1.37 (s,
3H); 13C NMR (100 MHz, CDCl3) δ 137.7, 128.5, 128.5, 127.9, 127.7, 127.7, 109.3, 79.1,




A solution of the azide 31 (2.4 g, 6.0 mmol) in THF (18 ml) was added dropwise to a stirred
suspension of LiAlH4 in THF (2 M solution in THF, 13 mL, 13 mmol) at −78 °C under
argon. The reaction mixture was stirred for 20 min, warmed up to 0 °C and then a 10%
aqueous sodium solution was added dropwise and diluted with CH2Cl2. The biphasic system
was stirred for 5 min and then separated. The aqueous phase was further extracted with
chloroform and the combined organic phases were washed with brine and dried over sodium
sulfate. Concentration of the organic layer under reduced pressure afforded the amine. The
amine (2.12 g, 5.74 mmol) was taken into anhydrous CH2Cl2. Triethylamine (1.00 mL, 7.46
mmol) was added followed by tosyl chloride (1.42 g, 7.46 mmol) (as a solid) and stirred at
room temperature for 4 h. Water was used to quench the reaction. The phases were separated
and the aqueous phase was further extracted with CH2Cl2, dried over sodium sulfate and
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concentrated under reduced pressure. Purification of the crude product by silica gel flash
column chromatography (30% EtOAc/hexanes provided 2.87 g (90%) of compound 32 as a
colorless oil over two steps.  (c 1.02, MeOH); 1H NMR (400 MHz, CDCl3) δ
7.64–7.67 (m, 2H), 7.13–7.28 (m, 12H), 4.72 (d, J = 11.2 Hz, 1H), 4.56 (d, J = 11.3 Hz, 1H),
4.20–4.28 (m, 3H), 3.97 (dd, J = 6.7, 8.0 Hz, 1H), 3.81–3.87 (m, 2H), 3.52 (dd, J = 4.5, 9.5
Hz, 1H), 3.35–3.38 (m, 1H), 3.14 (dd, J = 4.4, 9.5 Hz, 1H), 2.33 (s, 3H), 1.42 (s, 3H), 1.37
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 143.4, 138.1, 137.6, 137.2, 129.5, 128.4, 127.9,
127.7, 127.1, 109.0, 78.1, 76.1, 74.7, 73.1, 67.4, 65.5, 54.6, 26.5, 25.1, 21.5; HRMS (ESI)
calcd for [C29H35NO6S + H]+ 526.2263, found 526.2270.
N-((2R,3R,4S)-1,3-Bis(benzyloxy)-5-(tert-butyldimethylsilyloxy)-4-hydroxypentan-2-yl)-4-
methylbenzenesulfonamide (33)
A solution of acetonide 32 (2.5 g, 4.8 mmol) was taken into a 1:1 solution of methanol and
2N HCl and stirred at 40 °C. The reaction was monitored by TLC and following completion
was quenched by saturated solution of sodium bicarbonate, extracted with CH2Cl2, washed
with brine and dried over MgSO4, concentrated in vacuum to give the crude product. The
crude diol (2.4 g, 4.5 mmol) was taken into dry CH2Cl2. The solution was cooled to 0 °C
and triethylamine (0.75 mL, 5.4 mmol) was added followed by t-butyldimethylsilyl chloride
(1 M solution in CH2Cl2, 5.4 ml, 5.4 mmol) and a catalytic amount of DMAP. The reaction
was stirred at 0 °C and after 1 h, water was added to quench the reaction. The reaction
mixture was extracted with CH2Cl2, dried over sodium sulfate and concentrated under
reduced pressure. Purification of the crude product was accomplished by silica gel flash
column chromatography using 25% EtOAc/hexanes to provide compound 33 as a colorless
oil in 85% yield (2.42 g).  (c 0.67, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.66
(d, J = 8.2 Hz, 2H), 7.13–7.28 (m, 12H), 4.57 (d, J = 4.8 Hz, 2H), 4.26 (d, J = 4.5 Hz, 2H),
3.65–3.77 (m, 4H), 3.55 (ddd, J = 5.3, 9.6, 18.9 Hz, 2H), 3.38 (dd, J = 5.2, 9.8 Hz, 1H), 2.31
(s, 3H), 0.88 (s, 9H), 0.01 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 143.1, 138.3, 137.6,
137.5, 129.6, 128.9, 128.5, 128.1, 127.9, 127.3, 78.6, 73.8, 72.9, 71.6, 68.3, 63.6, 54.2, 25.9,




Sulfonamide 33 (2.2 g, 3.67 mmol) and triphenylphosphine (1.45 g, 5.5 mmol) were
dissolved in dry CH2Cl2 under argon/nitrogen. Diisopropyl azodicarboxylate (0.90 mL, 5.5
mmol) was added dropwise at 0 °C with stirring. The solution was warmed to room
temperature and stirred for 16 h. The reaction mixture was then filtered through a pad of
silica and concentrated in vacuo. The crude mixture was purified by flash silica gel column
chromatography to yield the corresponding N-tosylazetidine as a colorless oil. 1.5 g (2.6
mmol) of the N-tosylazetidine was dissolved in dry DME (26 mL) and the resulting solution
cooled to −60 °C. To this solution was added dropwise a dark-green solution of Na/
naphthalene in a dry DME (0.25 M solution prepared by the addition of 0.89 g of Na in a
0.25 M solution of naphthalene (5 g) in DME until the dark-green color persisted. After 30
min, brine was added to the solution and the aqueous phase was extracted with EtOAc. The
organic phase was dried (Na2SO4), concentrated in vacuum and the crude product filtered
through a small pad of silica (5% EtOAc/hexanes to remove naphthalene and then pure
EtOAc to elute azetidine 34 as a pale yellow oil in 70% yield over two steps (0.96 g).
 (c 0.67, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.27–7.33 (m, 10H), 4.46–4.52
(m, 4H), 4.18–4.21 (m, 1H), 3.87–3.96 (m, 3H), 3.75 (d, J = 6.6 Hz, 1H), 3.47–3.49 (d, J =
4.1 Hz, 2H), 0.88 (s, 9H), 0.01 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 138.2, 128.4, 127.7,
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74.7, 73.3, 72.4, 71.8, 64.0, 62.3, 61.6, 25.9, 18.3, −5.4; HRMS (ESI) calcd for
[C25H37NO3Si + H]+ 428.2621, found 428.2615.
((2R,3S,4R)-3-(Benzyloxy)-4-(benzyloxymethyl)-1-butylazetidin-2-yl)methanol (35a) and
((2R,3S,4R)-3-(Benzyloxy)-4-(benzyloxymethyl)-1-nonylazetidin-2-yl)methanol (35b)
The azetidine 34 (0.8 g, 1.9 mmol) and the aldehyde (butyraldehyde or nonyl aldehyde, 1.8
mmol ((0.16 mL for butyraldehyde and 0.30 mL for nonaldehyde) were mixed in
ClCH2CH2Cl and then treated with solid sodium triacetoxyborohydride (0.57 g, 2.7 mmol).
The mixture was stirred at rt under a nitrogen atmosphere for 16 h. The reaction mixture was
quenched by adding aqueous saturated sodium bicarbonate. The product was extracted with
CH2Cl2, dried over sodium sulfate, concentrated under reduced pressure, and purified by
silica gel flash column chromatography. A mixture of the alkylated product, butyl derivative
(0.69 g, 1.4 mmol) or nonyl derivative (0.81 g, 1.5 mmol) and TBAF (1 M in THF, 1.5
equiv, 2.25 ml) was stirred at room temperature for 4 h. The solvent was removed under
reduced pressure and the crude product was purified by flash silica gel column
chromatography using 100% EtOAc to provide compound 35a (0.5 g, 70% or 35b (0.6 g,
72%))) as a pale brown oil. 35a:  (c 0.67, MeOH); 1H NMR (400 MHz, CDCl3) δ
7.24–7.34 (m, 10H), 4.44–4.61 (m, 4H), 4.22 (dd, J = 5.2, 6.8 Hz, 1H), 4.06 (dd, J = 5.1,
12.4 Hz, 1H), 3.90 (dd, J = 3.0, 12.4 Hz. 1H), 3.72–3.76 (m, 2H), 3.46–3.48 (m, 2H), 2.76–
2.80 (m, 1H), 2.62–2.65 (m, 1H), 1.30–1.33 (m, 4H), 0.88 (t, J = 7.1 Hz, 3H); 13C NMR
(100 MHz, CDCl3) δ 138.2, 137.6, 128.5, 128.4, 127.9, 127.7, 127.6, 74.9, 73.4, 71.8, 71.6,
71.1, 64.8, 60.4, 49.7, 31.5, 20.6, 14.1; HRMS (ESI) calcd for [C23H31NO3 + H]+ 370.2382,
observed 370.2378.
35b:  (c 0.40, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.24–7.34 (m, 10 H), 4.45–
4.60 (m, 4H), 4.24 (dd, J = 5.5, 6.3 Hz, 1H), 4.06 (dd, J = 5.1, 12.4 Hz, 1H), 3.92 (dd, J =
3.1, 12.5 Hz, 1H), 3.70–3.76 (m, 2H), 3.47–3.49 (m, 2H), 2.77–2.80 (m, 1H), 2.64–2.67 (m,
1H), 1.24–1.36 (m, 14H), 0.86 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 138.1,
137.6, 128.5, 127.9, 127.7, 74.6, 73.4, 71.9, 71.2, 71.0, 65.1, 60.2, 50.1, 31.8, 29.5, 29.3,
29.0, 27.4, 22.6,14.1; HRMS (ESI) calcd for [C28H41NO3 + H]+ 440.3165, found 440.3169.
((2R,4R)-1-Butyl-3-hydroxyazetidine-2,4-diyl)dimethanol (22) and ((2R,4R)-3-Hydroxy-1-
nonylazetidine-2,4-diyl)dimethanol (23)
The dibenzyl compound (200 mg of 35a or 35b, 0.5 mmol and 0.45 mmol) was dissolved in
methanol and palladium chloride (10 mol%) was added and the reaction mixture was
subjected to hydrogenation (balloon) at room temperature for 4 h. The reaction mixture was
filtered through Celite and the solvent removed under reduced pressure. The crude product
was then washed with hexanes and dried over sodium sulfate to furnish compounds 22 and
23 as colorless oils in 65% (60 mg) and 70% yield (81 mg) respectively. 22:  (c
0.20, MeOH); 1H NMR (400 MHz, DMSO-d6) δ 4.49 (t, J = 6.2 Hz, 1H), 4.06–4.23 (m,
3H), 3.80–3.91 (m, 3H), 3.15–3.23 (m, 2H), 1.49–1.59 (m, 2H), 1.3–1.32 (m, 2H), 0.88 (t, J
= 7.3 Hz, 3H); 13C NMR (100 MHz, DMSO-d6) δ 77.1, 71.9, 64.3, 58.8, 57.6, 50.6, 28.4,
20.9, 13.9; HRMS (ESI) calcd for [C9H19NO3 + H]+ 190.1443, found 190.1445. 23:
 (c 0.60, MeOH); 1H NMR (400 MHz, DMSO-d6) δ 4.48 (t, J = 6.3 Hz, 1H),
4.06–4.18 (m, 3H), 3.77–3.91 (m, 3H), 3.12–3.19 (m, 2H), 1.50–1.57 (m, 2H), 1.19–1.22
(m, 12H), 0.78 −0.80 (t, 7.2 Hz, 3H); 13C NMR (100 MHz, DMSO-d6) δ 77.1, 71.7, 64.5,
59.1, 57.7, 50.1, 33.1, 30.5, 30.3, 30.2, 27.8, 26.6, 23.7, 14.4; HRMS (ESI) calcd for
[C14H29NO3 + H]+ 260.2226, found 260.2225.
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General procedures for compounds 37–41a, 41b, 24 and 25
The synthesis of compounds 37–41a, 41b, 24 and 25 (Scheme 8) follow the procedures for
the synthesis of compounds 31–35a, 35b, 22 and 23 (Scheme 7).
(R)-4-((1R,2R)-2-Azido-1,3-bis(benzyloxy)propyl)-2,2-dimethyl-1,3-dioxolane (37)
Compound 36 was synthesized as described previously in the literature.36 Compound 37
was obtained as a colorless oil in 70%.  (c 1.0, MeOH); 1H NMR (400 MHz,
CDCl3) δ 7.29–7.37 (m, 10H), 4.55–4.73 (m, 4H), 4.25–4.28 (m, 1H), 3.98–4.02 (m, 1H),
3.70–3.82 (m, 3H), 3.54–3.60 (m, 2H), 1.42 (s, 3H), 1.37 (s, 3H); 13C NMR (100 MHz,
CDCl3) 137.8, 137.6, 129.5, 128.4, 128.3, 127.8, 127.1, 109.3, 78.3, 74.5, 73.4, 69.1, 65.9,
62.1, 26.4, 25.6; HRMS (ESI) calcd for [C22H27N3O4 + H]+ 398.2080, found 398.2087.
N-((1R,2R)-1,3-Bis(benzyloxy)-1-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)propan-2-yl)-4-
methylbenzenesulfonamide (38)
Compound 38 was obtained as a colorless oil in 90%.  (c 0.72, MeOH); 1H NMR
(400 MHz, CDCl3) δ 7.65–7.68 (m, 2H), 7.17–7.32 (m, 12H), 4.24–4.46 (m, 4H), 4.10 (q, J
= 7.15 Hz, 1H), 3.94 (dd, J = 6.6, 8.1 Hz, 1H), 3.53–3.65 (m, 3H), 3.43 (t, J = 4.88 Hz, 1H),
3.34 (dd, J = 7.02, 9.46 Hz, 1H), 2.31 (s, 3H), 1.39 (s, 3H), 1.30 (s, 3H); 13C NMR (100
MHz, CDCl3) δ ?143.2, 137.8, 137.4, 129.5, 128.4, 128.3, 127.8, 127.1, 109.4, 76.5, 73.2,
73.1, 68.8, 66.2, 60.3, 53.9, 26.2, 25.6, 21.4, 20.1, 14.2; HRMS (ESI) calcd for
[C29H35NO6S + H]+ 526.2263, found 526.2267.
N-((2R,3R,4R)-1,3-Bis(benzyloxy)-5-(tert-butyldimethylsilyloxy)-4-hydroxypentan-2-yl)-4-
methylbenzenesulfonamide (39)
Compound 39 was obtained as a colorless oil in 89%.  (c 0.51, MeOH); 1H NMR
(400 MHz, CDCl3) δ 7.66 (d, J = 8.2 Hz, 2H), 7.13–7.28 (m, 12H), 4.57 (d, J = 11.1 Hz,
2H), 4.25 (d, J = 4.5 Hz, 2H), 3.65–3.77 (m, 4H), 3.56 (ddd, J = 5.3, 9.6, 18.9 Hz, 2H), 3.38
(dd, J = 5.2, 9.8 Hz, 1H), 2.31 (s, 3H) 0.88 (s, 9H) 0.01 (s, 6H); 13C NMR (100 MHz,
CDCl3) δ 143.3, 137.9, 137.5, 137.4, 129.6, 128.4, 128.3, 127.9, 127.8, 127.7, 127.1, 75.6,
73.5, 73.1, 70.3, 68.1, 63.1, 63.5, 60.3, 53.3, 25.9, 21.5, 21.1, 18.2, 14.2, −5.4; HRMS (ESI)
calcd for [C32H45NO6SSi + H]+ 600.2815, found 600.2819.
(2R,3R,4S)-3-(Benzyloxy)-2-(benzyloxymethyl)-4-((tert-
butyldimethylsilyloxy)methyl)azetidine (40)
Compound 40 was obtained as a colorless oil in 53%.  (c 0.67, MeOH); 1H NMR
(400 MHz, CDCl3) δ 7.20–7.29 (m, 10H), 4.41–4.52 (m, 4H), 3.79–3.86 (m, 3H), 3.76 (d, J
= 6.6 Hz, 1H), 3.54–3.56 (m, 2H), 3.41–3.44 (m, 2H), 0.84 (s, 9H), 0.01 (6H); 13C NMR
(100 MHz, CDCl3) δ 138.2, 128.4, 127.7, 74.7, 73.3, 72.4, 71.8, 64.0, 62.3, 61.6, 25.9, 18.3,
−5.4; HRMS (ESI) calcd for [C25H37NO3Si + H]+ 428.2621, found 428.2621.
((2R,3S,4S)-3-(Benzyloxy)-4-(benzyloxymethyl)-1-butylazetidin-2-yl)methanol (41a)
Compound 41a was obtained as a pale yellow oil in 73%.  (c 1.0, MeOH); 1H NMR
(400 MHz, CDCl3) δ ?7.28–7.34 (m, 10H), 4.42–4.56 (m, 4H), 4.23 (dd, J = 5.2, 6.8 Hz,
1H), 4.06 (dd, J = 5.1, 12.4 Hz, 1H), 3.91 (t, J = 5.3 Hz, 1H), 3.41–3.57 (m, 2H), 3.11–3.17
(m, 2H), 2.56–2.65 (m, 2H), 1.26–1.38 (m, 4H), 0.87 (t, J = 7.2 Hz, 3H); 13C NMR (100
MHz, CDCl3) δ 138.2, 138.0, 128.4, 128.4, 127.8, 127.6, 127.5, 72.6, 71.7, 71.5, 71.2, 69.9,
61.1, 57.7, 30.5, 20.5, 13.9; HRMS (ESI) calcd for [C23H31NO3 + H]+ 370.2382, found
370.2387.
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Compound 41b was obtained as a pale yellow oil in 80%.  (c 1.1, MeOH); 1H
NMR (400 MHz, CDCl3) δ ?7.26–7.34 (m, 10H), 4.46–4.53 (m, 4H), 3.98 (d, J = 5.4 Hz,
1H), 3.37–3.64 (m, 6H), 2.78–2.82 (m, 2H), 1.24–1.34 (m, 14H), 0.87 (t, J = 7.3 Hz,
3H); 13C NMR (100 MHz, CDCl3) δ 137.8, 137.4, 128.5, 128.4, 128.1, 127.9, 127.7, 73.4,
72.9, 71.9, 71.4, 70.7, 69.9, 60.3, 58.2, 31.8, 30.1, 29.4, 29.3, 29.2, 27.1, 26.5, 22.6, 14.1;
HRMS (ESI) calcd for [C28H41NO3 + H]+ 440.3165, found 440.3169.
((2R,3s,4S)-1-Butyl-3-hydroxyazetidine-2,4-diyl)dimethanol (24)
Compound 24 was obtained as a pale yellow oil in 74%. 1H NMR (400 MHz, MeOD) δ 4.26
(t, J = 6.6 Hz, 1H), 4.00–4.04 (m, 2H), 3.81 (d, J = 4.2 Hz, 4H), 3.20–3.23 (m, 2H), 1.61–
1.65 (m, 2H), 1.29–1.35 (m, 2H), 0.88 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, MeOD) δ
77.5, 63.2, 59.2, 57.4, 49.9, 27.7, 20.8, 13.9; HRMS (ESI) calcd for [C9H19NO3 + H]+
190.1443, found 190.1448.
((2R,3s,4S)-3-Hydroxy-1-nonylazetidine-2,4-diyl)dimethanol (25)
Compound 25 was obtained as a pale yellow oil in 80%. 1H NMR (400 MHz, MeOD) 4.25
(t, J = 6.6, 1H), 4.01–4.05 (m, 2H,), 3.79–3.82 (m, 4H), 3.20–3.24 (m, 2H), 1.63–1.66 (m,
2H), 1.20–1.28 (m, 12H), 0.80 (t, J = 6.8, 3H); 13C NMR (100 MHz, MeOD) δ 77.5, 63.2,
59.3, 57.7, 49.9, 33.0, 30.5, 30.3, 30.2, 27.6, 25.8, 23.7, 14.5; HRMS (ESI) calcd for
[C14H29NO3 + H]+ 260.2226, found 260.2223.
General procedures for compounds 43–47a, 47b, 26 and 27
The synthesis of compounds 43–47a, 47b, 26 and 27 (Scheme 9) follows the procedures for
the synthesis of compounds 31–35a, 35b, 22 and 23 (Scheme 7).
(R)-4-((1S,2S)-2-Azido-1,3-bis(benzyloxy)propyl)-2,2-dimethyl-1,3-dioxolane (43)
Compound 42 was synthesized as described previously in the literature.36 Compound 43
was obtained from compound 42 as a colorless oil in 70%.  (c 0.67, MeOH); 1H
NMR (400 MHz, CDCl3) δ 7.33–7.38 (m, 10H), 4.70 (d,d, J = 12.7 Hz, 6.1 Hz, 2H), 4.61
(d,d J = 6.0 Hz, 6.4 Hz, 2H), 4.20 (q, J = 6.3 Hz, 1H), 4.05 (dd, J = 6.4, 8.3 Hz, 1H), 3.90 (d,
J = 2.2 Hz, 2H), 3.68–3.76 (m, 3H), 1.42 (s, 3H), 1.37(s, 3H); 13C NMR (100 MHz, CDCl3)
δ 137.8, 128.4, 127.8, 109.3, 79.1, 75.2, 73.9, 73.4, 69.6, 66.5, 62.5, 26.6, 25.2; [α] 24D 20
(c 0.67, MeOH). HRMS (ESI) calcd for [C22H27N3O4 + H]+ 398.2080, found 398.2082.
N-((1S,2S)-1,3-Bis(benzyloxy)-1-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)propan-2-yl)-4-
methylbenzenesulfonamide (44)
Compound 44 was obtained as a colorless oil in 88%.  (c 0.80, MeOH); 1H NMR
(400 MHz, CDCl3) δ 7.65–7.68 (m, 2H), 7.17–7.32 (m, 12H), 4.75 (d, J = 11.2 Hz, 1H),
4.57 (d, J = 11.3 Hz, 1H), 4.23–4.30 (m, 3H), 3.98 (dd, J = 6.7, 8.0 Hz, 1H), 3.82–3.88 (m,
2H), 3.54 (dd, J = 4.5, 9.5 Hz, 1H), 3.35–3.38 (m, 1H), 3.15 (dd, J = 4.4, 9.5 Hz, 1H), 1.42
(s, 3H), 2.39 (s, 3H), 1.31 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 143.5, 138.1, 137.5,
137.4, 129.6, 128.4, 127.9, 127.7, 127.2, 109.1, 75.9, 74.7, 73.1, 67.3, 65.5, 54.6, 26.4, 24.9,
21.5; HRMS (ESI) calcd for [C29H35NO6S + H]+ 526.2263, found 526.2265.
N-((2S,3S,4R)-1,3-Bis(benzyloxy)-5-(tert-butyldimethylsilyloxy)-4-hydroxypentan-2-yl)-4-
methylbenzenesulfonamide (45)
Compound 45 was obtained as a colorless oil in 87%.  (c 1.02, MeOH); 1 H NMR
(400 MHz, CDCl3) δ 7.65 (d, J = 8.2 Hz, 2H), 7.13–7.28 (m, 12H), 4.57 (d, J = 11.2 Hz,
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2H), 4.25 (d, J = 4.5 Hz, 2H), 3.65–3.77 (m, 4H), 3.56 (ddd, J = 5.3, 9.6, 18.9 Hz, 2H), 3.38
(dd, J = 5.2, 9.8 Hz, 1H), 2.31 (s, 3H), 0.88 (s, 9H), 0.01 (s, 6H); 13C NMR (100 MHz,
CDCl3) δ 143.1, 138.1, 137.6, 137.5, 129.5, 128.3, 127.9, 127.7, 127.6, 127.2, 78.6, 73.7,
72.9, 71.5, 68.3, 63.6, 54.1, 25.9, 21.4, 18.2, −5.4; HRMS (ESI+) calcd for [C32H45NO6SSi
+ H]+ 600.2815, found 600.2819.
(2S,3S,4S)-3-(Benzyloxy)-2-(benzyloxymethyl)-4-((tert-
butyldimethylsilyloxy)methyl)azetidine (46)
Compound 46 was obtained as a colorless oil in 55% yield.  (c 2.02, MeOH). 1H
NMR (400 MHz, CDCl3) δ 7.27–7.33 (m, 10H), 4.46–4.52 (m, 4H), 4.18–4.21 (m, 1H),
3.87–3.96 (m, 3H), 3.75 (d, J = 6.6 Hz, 1H), 3.48 (d, J = 4.1 Hz, 2H), 0.88 (s, 9H), 0.01
(6H); 13C NMR (100 MHz, CDCl3) δ ?138.1, 128.4, 127.7, 73.3, 72.3, 71.8, 63.9, 62.3,
61.5, 25.9, 18.2, −5.3. HRMS (ESI) calcd for [C25H37NO3Si + H]+ 428.2621, found
428.2618.
((2S,3R,4S)-3-(Benzyloxy)-4-(benzyloxymethyl)-1-butylazetidin-2-yl)methanol (47a)
Compound 47a was obtained as a pale brown oil in 72%.  (c 1.20, MeOH); 1H
NMR (400 MHz, CDCl3) δ 7.25–7.34 (m, 10H), 4.45–4.61 (m, 4H), 4.23 (dd, J = 5.2, 6.8
Hz, 1H), 4.06 (dd, J = 5.1, 12.4 Hz, 1H), 3.91 (dd, J = 3.0, 12.4 Hz, 1H), 3.70–3.74 (m, 2H),
3.47–3.49 (m, 2H), 2.76–2.82 (m, 1H), 2.63–2.66 (m, 1H), 1.30–1.32 (m, 4H), 0.88 (t, J =
7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 138.2, 137.6, 128.4, 127.9, 127.6, 74.9, 73.4,
71.9, 71.5, 71.1. 64.9, 60.4, 49.8, 31.4, 20.6, 14.1; HRMS (ESI) calcd for [C23H31NO3 +
H]+ 370.2382, found 370.2383.
((2S,3R,4S)-3-(Benzyloxy)-4-(benzyloxymethyl)-1-nonylazetidin-2-yl)methanol (47b)
Compound 47b was obtained as a pale brown oil in 76%.  (c 1.30, MeOH); 1H
NMR (400 MHz, CDCl3) δ 7.24–7.34 (m, 10H), 4.45–4.61 (m, 4H), 4.22 (dd, J = 5.5, 6.3
Hz, 1H), 4.06 (dd, J = 5.1, 12.4 Hz, 1H), 3.91 (dd, J = 3.1, 12.5 Hz, 1H), 3.68–3.76 (m, 2H),
3.46–3.48 (m, 2H), 2.73–2.80 (m, 1H), 2.61–2.66 (m, 1H), 1.25–1.36 (m, 14H), 0.87 (t, J =
7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 138.2, 137.7, 128.5, 127.7, 127.6, 74.9, 73.4,
71.9, 71.6, 71.1, 64.8, 60.4, 50.1, 31.9, 29.6, 29.4, 27.5, 22.7, 14.1; HRMS (ESI) calcd for
[C28H41NO3 + H]+ 440.3165, found 440.3168.
((2S,4S)-1-Butyl-3-hydroxyazetidine-2,4-diyl)dimethanol (26)
Compound 26 was obtained as a pale brown oil in 68% yield.  (c 0.20, MeOH). 1H
NMR (400 MHz, MeOD) δ 4.52 (t, J = 6.2 Hz, 1H), 4.06–4.23 (m, 3H), 3.80–3.91 (m, 3H),
3.15–3.23 (m, 2H), 1.51–1.64 (m, 2H), 1.30–1.35 (m, 2H), 0.88 (t, J = 7.3 Hz, 3H); 13C
NMR (100 MHz, MeOD) δ 77.1, 71.9, 64.3, 58.8, 57.5, 50.5, 28.3, 20.1, 13.9; HRMS (ESI)
calcd for [C9H19NO3 + H]+ 190.1443, found 190.1446.
((2S,4S)-3-Hydroxy-1-nonyl-azetidine-2,4-diyl)dimethanol (27)
Compound 27 was obtained as a pale brown oil in 74%.  (c 0.60, MeOH); 1H
NMR (400 MHz, MeOD) δ 4.48 (t, J = 6.3, 1H), 4.06–4.18 (m, 3H), 3.75–3.88 (m, 3H),
3.24–3.27 (m, 2H), 1.56–1.63 (m, 2H), 1.21–1.25 (m, 12H), 0.78–0.81 (t, 7.21, 3H); 13C
NMR (100 MHz, MeOD) δ 77.1, 71.7, 64.5, 59.1, 57.7, 50.9, 33.1, 30.7, 30.4, 27.8, 27.3,
26.6, 23.7, 14.4; HRMS (ESI) calcd for [C14H29NO3 + H]+ 260.2226, found 260.2220.
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Microsome preparations from C57BL/6 mouse and LE rat testes
Testes in 5 g batches were placed in a 50 mL culture tube containing 25 mL of Reagent B
(0.5 M Tris, 2.0 M Sucrose) and reagent A [Reagent A: 20 µL antipain, 20 µL leupeptin, 200
µL aprotinin, 110 µL APMSF, 372 mg KCl and 18.5 mL milliQ water (all protease
inhibitors were made as 1 mg/ml stock)]. The testes were minced with scissors, and then
blended by 10 sec bursts repeated 2–3 times at a time on Power Gen 700 (Fisher Scientific)
while on ice. The homogenate was centrifuged at 7500 rpm for 10 min at 4 °C using a SW28
rotor (5660g). The resulting supernatant was collected and centrifuged at 23500 rpm for 1 h
at 4 °C in a SW40 rotor. The supernatant was discarded and the pellet containing the
microsomes was suspended in 600 µL of Reagent D (Reagent C, 200 mM DTT, 0.1 M
EDTA, 10 mM UDP-glucose and 10% CHAPSO) and dispersed by passage through a 25
gauge needle followed by an insulin needle. The microsome suspension was stored as 100 µl
aliquots in microcentrifuge tubes, flash frozen in liquid nitrogen for 1–2 min, and kept at
−80 °C, and used as needed. (Reagent C contained 250 µL 10% N-laurosarcosine, 6.25 mL
0.2 M HEPES, 5 mL Glycerol, 250 µL 2% NaN3, 250 µL 0.1 M EDTA, 2.25 mL Reagent A
and 250 µL 200 mM DTT)
Ceramide-specific glucosyltransferase assay
The following solutions were added to each tube: 295 µL of Assay mix (50 mM HEPES; pH
7.4, reagent A, 5 mM MnCl2, 10mM phosphatidylcholine, 50 µM CBE, 1 mM EDTA and
10 mM UDP-Glucose), 145 µL water, 50 µL iminosugar and 100 µg testicular microsomes.
Control tubes contained the same components except microsomes. Reactions were initiated
by the addition of 3 µL of BSA-ceramide, and incubated at 37 °C for 30 min, then
terminated by addition of 1 mL of 2:1 (v/v) chloroform:methanol, vortexed and incubated at
room temperature for 30–60 min to allow phase separation. The upper phase and the mid-
layer were removed and discarded, and 500 µL of chloroform:methanol:water (3:48:47) was
added to the bottom layer, vortexed and allowed to sit for 15 min at room temperature. The
resulting upper phase was again removed and 100 µL of chloroform:methanol (2:1) was
added, and then the sample tubes were dried in a vortex evaporator overnight.
Thin layer chromatography (TLC)
TLC plates were pre-treated (Whatman silica gel 60 A, 20×20 cm, layer thickness 250 µm)
by immersion in chloroform:methanol:water (50:50:15) for 5 min, air dried for 10 min, then
immersed in 5% sodium borate (prepared in methanol) for 1 min, dried and heated at 120 °C
for 1.5 h. The dried sample tubes were reconstituted with 100 µL chloroform:methanol (2:1),
vortexed and 20 µL was then spotted onto the plates at the origin. The spotted plates were
air-dried and placed in a sealed TLC chamber saturated with of chloroform:methanol:water
(60:30:5), and run approximately for 1 h until the solvent reached within 1 cm from the top
of the plate.
Detection and quantitation of substrate/product
The TLC plate was documented using UV transilluminator (302 nm) and analyzed using
AlphaEase (Fluorchem SP) software. The IDV values were plotted against iminosugar
concentration using Sigma Plot 10. Linear regression plot was used to determine IC50values.
Testicular glucosidase assay
The assay was carried out in 96 well plates. 50 µL of 4- methylumbelliferyl beta-D-
glucoside (MUG; Sigma, St. Louis, 3 mg/ml concentration) was added to each well using a
multi-channel pipette, followed by 10 µL iminosugar dilutions (0, 5, 10, 50, 100, 500 and
1000 µM) added from left to the right so as to have increasing concentration of the
iminosugar from top to the bottom of the plate. 50 µL of testicular microsome (1 µg/µl) was
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then added to each well using a multi-channel pipette in the first column. Another multi-
channel pipette was kept ready loaded with terminator solution (100 µL 1M sodium
carbonate, pH 10.7) and was added simultaneously to this row. Microsome was then added
to the remaining rows after setting the timer to 1 min. Every 1 min the terminator solution
was added to each row until the 12th row. Absorbance was then detected at 360/460 nm
using a Synergy HT Multi-Mode Microplate Reader (BioTek). The absorbance values were
subtracted from background (MUG only). Linear regression plot created using prism
software (Graph Pad Prism 5) was used to determine the IC50 values.
Glycosidase inhibition assays
Chemicals and enzymes for the inhibition kinetics were purchased from Sigma Aldrich (St.
Louis, MO) unless otherwise noted. Non-linear regression analysis was performed using
SigmaPlot (Systat Software, Inc., San Jose, CA). Assays were carried out in 96-well plate
format, each well containing 2 µL of compound, 10 µL of substrate and 78 µL of buffer. The
reaction was started by addition of 10 µL of enzyme and incubated for 4–5 min at room
temperature. The reaction was quenched by addition of 200 µL of 0.2 M sodium borate (pH
9.8). Buffer conditions, substrate and enzyme concentrations were similar to those
described.37 The Km values for each substrate/enzyme combination were determined
experimentally (Figure 7), and for the inhibition assays the substrate concentration was
equal to Km. α-Glucosidase (Saccharomyces cerevisiae) was assayed at 0.49 µg/ml in
sodium phosphate buffer (50 mM, pH 6.5) with 0.35 mM 4-nitrophenyl α-
Dglucopyranoside. β-Glucosidase (almond) was assayed at 0.83 µg/ml in sodium acetate
buffer (50 mM, pH 5.0) with 3.6 mM 4-nitrophenyl β-D-glucopyranoside. α-Galactosidase
(green coffee beans) was assayed at 5.0 µg/ml in sodium phosphate buffer (50 mM, pH 6.5)
with 0.27 mM 4-nitrophenyl α-Dgalactopyranoside. β-Galactosidase (Escherichia coli) was
assayed at 3.6 µg/ml in sodium phosphate buffer (50 mM, pH 7.3) with 0.13 mM 4-
nitrophenyl β-D-galactopyranoside. α-mannosidase (jack bean) was assayed at 1.7 µg/ml in
sodium citrate buffer (50 mM, pH 4.5) with 2.7 mM 4-nitrophenyl α-Dmannpyranoside. β-
Mannosidase (Roman snail) was assayed at 4.1 µg/ml in acetate buffer (50 mM, pH 4.0)
with 0.7 mM 4-nitrophenyl β-D-mannopyranoside. Absorbance was measured at 405 nm
using a Spectra-Max 340PC plate reader (Molecular Devices, Sunnyvale, CA). IC50 values
were determined by fitting data to equation (1), where A is the relative activity, [I] is the
concentration of the compound, and n is the Hill slope coefficient.
Equation (1)
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We gratefully acknowledge financial support from NIH (NICHD Reproductive Branch Contract
HHSN275200503400C). We also thank Dr. Victor Young and Benjamin E. Kucera for obtaining X-ray
crystallographic data, Dr. Ramappa Chakrasali for some initial efforts with the chemistry, and Brian Kern for help
with the microsome preparations. We also thank Kwon Ho Hong for assistance with the modeling studies.
REFERENCES
1. (a) Finer LB, Henshaw SK. Perspect. Sex. Repro. Health. 2006; 38:90–96.(b) Jones RK, Zolna
MRS, Stanley K, Henshaw, Finer LB. Perspect. Sex. Repro. Health. 2008; 40:6–16.(c) Page ST,
Lee et al. Page 23













Amory JK, Bremner WJ. Endocr. Rev. 2008; 29:465–493. [PubMed: 18436704] (d) Liu PY,
Swerdloff RS, Wang C. Contraception. 2010; 82:471–475. [PubMed: 20933121] (e) Wang C,
Swerdloff RS. Curr. Opin. Urol. 2010; 20:520–524. [PubMed: 20808223]
2. Mruk DD. Trends Endocrinol. Metab. 2008; 19:57–64. [PubMed: 18291665]
3. Gu ZP, Mao BY, Wang YX, Zhang RA, Tan YZ, Chen ZX, Cao L, You GD, Segal SJ. Asian J.
Androl. 2000; 2:283–287. [PubMed: 11202417]
4. Jones AR. Aust. J. Biol. Sci. 1983; 36:333–350. [PubMed: 6362633]
5. (a) Tash JS, Attardi B, Hild SA, Chakrasali R, Jakkaraj SR, Georg GI. Biol. Reprod. 2008; 78:1127–
1138. [PubMed: 18218612] (b) Tash JS, Chakrasali R, Jakkaraj SR, Hughes J, Smith SK,
Hornbaker K, Heckert LL, Ozturk SB, Hadden MK, Kinzy TG, Blagg BSJ, Georg GI. Biol. Reprod.
2008; 78:1139–1152. [PubMed: 18218611] (c) Su L, Cheng CY, Mruk DD. Int. J. Biochem. Cell
Biol. 2010; 42:1864–1875. [PubMed: 20713173] (d) Chung SS, Wang X, Roberts SS, Griffey SM,
Reczek PR, Wolgemuth DJ. Endocrinology. 2011; 152:2492–2502. [PubMed: 21505053]
6. van der Spoel AC, Jeyakumar M, Butters TD, Charlton HM, Moore HD, Dwek RA, Platt FM. Proc.
Natl. Acad. Sci. USA. 2002; 99:17173–17178. [PubMed: 12477936]
7. (a) Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, Platt F, Butters T, Dwek R,
Moyses C, Gow I, Elstein D, Zimran A. Lancet. 2000; 355:1481–1485. [PubMed: 10801168] (b)
Elstein D, Hollak C, Aerts JMFG, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M,
Platt FM, Butters TD, Dwek RA, Zimran A. J. Inherited Metab. Dis. 2004; 27:757–766. [PubMed:
15505381] (c) Heitner R, Elstein D, Aerts J, van Weely S, Zimran A. Blood Cell Mol. Dis. 2002;
28:127–133.(d) Elstein D, Dweck A, Attias D, Hadas-Halpern I, Zevin S, Altarescu G, Aerts JFMG,
van Weely S, Zimran A. Blood. 2007; 110:2296–2301. [PubMed: 17609429] (e) Dulsat C, Mealy
N. Drug Future. 2009; 34:147–149.
8. (a) Stutz, AE. Iminosugars as Glycosidase Inhibitors: Nojirimycin and Beyond. Germany: Wiley-
VCH: Weinheim; 1999. (b) Compain, P.; Martin, OR. Iminosugars: From Synthesis to Therapeutic
Applications. Germany: Wiley-VCH: Weinheim; 2007. (c) Horne G, Wilson FX, Tinsley J,
Williams DH, Storer R. Drug Discov. Today. 2011; 16:107–118. [PubMed: 20817006] (d) Sorbera
LA, Castaner J, Bayes M. Drug Future. 2003; 28:229–236.
9. Butters TD, Dwek RA, Platt FM. Glycobiology. 2005; 15:R43–R52.
10. Walden CM, Sandhoff R, Chuang CC, Yildiz Y, Butters TD, Dwek RA, Platt FM, van der Spoel
AC. J. Biol. Chem. 2007; 282:32655–32664. [PubMed: 17848577]
11. Bone W, Walden CM, Fritsch M, Voigtmann U, Leifke E, Gottwald U, Boomkamp S, Platt FM,
van der Spoel AC. Reprod. Biol. Endocrinol. 2007; 5:1. [PubMed: 17241468]
12. Amory JK, Muller CH, Page ST, Leifke E, Pagel ER, Bhandari A, Subramanyam B, Bone W,
Radlmaier A, Bremner WJ. Hum. Reprod. 2007; 22:702–707. [PubMed: 17067996]
13. (a) Butters TD, van den Broek LAGM, Fleet GWJ, Krulle TM, Wormald MR, Dwek RA, Platt
FM. Tetrahedron: Asymmetry. 2000; 11:113–124.(b) Faugeroux V, Genisson Y, Andrieu-Abadie
N, Colie S, Levade T, Baltas M. Org. Biomol. Chem. 2006; 4:4437–4439. [PubMed: 17268635]
(c) Butters TD, Dwek RA, Platt FM. Chem. Rev. 2000; 100:4683–4696. [PubMed: 11749362] (d)
Butters TD, Dwek RA, Platt FM. Curr. Top. Med. Chem. 2003; 3:561–574. [PubMed: 12570866]
(e) Mellor HR, Platt FM, Dwek RA, Butters TD. Biochem. J. 2003; 374:307–314. [PubMed:
12769816] (f) van der Spoel ACJM, Butters TD, Dwek RA. U.S. patent 20040019082. 2004(g)
Boucheron C, Desvergnes V, Compain P, Martin OR, Lavi A, Mackeen M, Wormald M, Dwek R,
Butters TD. Tetrahedron: Asymmetry. 2005; 16:1747–1756.(h) Li HQ, Liu T, Zhang YM, Favre S,
Bello C, Vogel P, Butters TD, Oikonomakos NG, Marrot J, Bleriot Y. ChemBioChem. 2008;
9:253–260. [PubMed: 18188862] (i) Deschamp J, Mondon M, Nakagawa S, Kato A, Alonzi DS,
Butters TD, Zhang Y, Sollogoub M, Bleriot Y. Biorg. Med. Chem. 2012; 20:641–649.
14. Ghisaidoobe A, Bikker P, de Bruijn ACJ, Godschalk FD, Rogaar E, Guijt MC, Hagens P, Halma
JM, van't Hart SM, Luitjens SB, van Rixel VHS, Wijzenbroek M, Zweegers T, Donker-Koopman
WE, Strijland A, Boot R, van der Marel G, Overkleeft HS, Aerts JMFG, van den Berg RJBHN.
ACS Med. Chem. Lett. 2011; 2:119–123.
15. (a) Wennekes T, van den Berg RJBHN, Donker W, van der Marel GA, Donker W, van der Marel
GA, Strijland A, Aerts JMFG, Overkleeft HS. J. Org. Chem. 2007; 72:1088–1097. [PubMed:
17243712] (b) Ardes-Guisot N, Alonzi DS, Reinkensmeier G, Butters TD, Norez C, Becq F,
Shimada Y, Nakagawa S, Kato A, Bleriot Y, Sollogoub M, Vauzeilles B. Org. Biomol. Chem.
Lee et al. Page 24













2011; 9:5373–5388. [PubMed: 21512716] (c) Wennekes T, Meijer AJ, Groen AK, Boot RG,
Groener JE, van Eijk M, Ottenhoff R, Bijl N, Ghauharali K, Song H, O'Shea TJ, Liu HL, Yew N,
Copeland D, van den Berg RJ, van der Marel GA, Overkleeft HS, Aerts JM. J. Med. Chem. 2010;
53:689–698. [PubMed: 20000679]
16. (a) Diot JD, Moreno IG, Twigg G, Mellet CO, Haupt K, Butters TD, Kovensky J, Gouin SG. J.
Org. Chem. 2011; 76:7757–7768. [PubMed: 21830816] (b) Orwig SD, Tan YL, Grimster NP, Yu
Z, Powers ET, Kelly JW, Lieberman RL. Biochemistry. 2011; 50:10647–10657. [PubMed:
22047104]
17. Lenagh-Snow GMJ, Araujo N, Jenkinson SF, Rutherford C, Nakagawa S, Kato A, Yu CY,
Weymouth-Wilson AC, Fleet GWJ. Org. Lett. 2011; 13:5834–5837. [PubMed: 21985023]
18. Pascher I, Sundell S. Chem. Phys. Lipids. 1977; 20:175–191.
19. Boyer FD, Hanna I, Nolan SP. J. Org. Chem. 2001; 66:4094–4096. [PubMed: 11375046]
20. Bernet B, Vasella A. Helv. Chim. Acta. 1979; 62:1990–2016.
21. Skaanderup PR, Hyldtoft L, Madsen R. Monatsh. Chem. 2002; 133:467–472.
22. AbdelMagid AF, Carson KG, Harris BD, Maryanoff CA, Shah RD. J. Org. Chem. 1996; 61:3849–
3862. [PubMed: 11667239]
23. (a) Michaut A, Rodriguez J. Angew. Chem. Int. Ed. 2006; 45:5740–5750.(b) Godin G, Garnier E,
Compain P, Martin OR, Ikeda K, Asano N. Tetrahedron Lett. 2004; 45:579–581.(c) Chang MY,
Kung YH, Ma CC, Chen ST. Tetrahedron. 2007; 63:1339–1344.
24. Bergmeier SC, Seth PP. Tetrahedron Lett. 1999; 40:6181–6184.
25. Liu HJ, Yip J, Shia KS. Tetrahedron Lett. 1997; 38:2253–2256.
26. Sharpless KB, Amberg W, Bennani YL, Crispino GA, Hartung J, Jeong KS, Kwong HL,
Morikawa K, Wang ZM, Xu DQ, Zhang XL. J. Org. Chem. 1992; 57:2768–2771.
27. (a) Nash RJ, Kato A, Yu CY, Fleet GWJ. Future Med. Chem. 2011; 3:1513–1521. [PubMed:
21882944] (b) Tajima Y, Saito S, Ohno K, Tsukimura T, Tsujino S, Sakuraba H. J. Hum. Genet.
2011; 56:440–446. [PubMed: 21471980] (c) Parenti G, Zuppaldi A, Pittis MG, Tuzzi MR,
Annunziata I, Meroni G, Porto C, Donaudy F, Rossi B, Rossi M, Filocamo M, Donati A, Bembi B,
Ballabio A, Andria G. Mol. Ther. 2007; 15:508–514. [PubMed: 17213836] (d) Sugawara K,
Tajima Y, Kawashima I, Tsukimura T, Saito S, Ohno K, Iwamoto K, Kobayashi T, Itoh K,
Sakuraba H. Mol. Genet. Metab. 2009; 96:233–238. [PubMed: 19181556] (e) Horne G, Wilson
FX. Prog. Med. Chem. 2011; 50:135–176. [PubMed: 21315930]
28. (a) Clinch K, Evans GB, Frohlich RFG, Furneaux RH, Kelly PM, Legentil L, Murkin AS, Li L,
Schramm VL, Tyler PC, Woolhouse AD. J. Med. Chem. 2009; 52:1126–1143. [PubMed:
19170524] (b) Guan R, Ho MC, Almo SC, Schramm VL. Biochemistry. 2011; 50:1247–1254.
[PubMed: 21197954] (c) Basso LA, Santos DS, Shi W, Furneaux RH, Tyler PC, Schramm VL,
Blanchard JS. Biochemistry. 2001; 40:8196–8203. [PubMed: 11444965]
29. (a) Risseeuw MDP, van den Berg RJBHN, Donker-Koopman WE, van der Marel GA, Aerts
JMFG, Overhand M, Overkleeft HS. Bioorg. Med. Chem. Lett. 2009; 19:6600–6603. [PubMed:
19853441] (b) Kato A, Kato N, Kano E, Adachi I, Ikeda K, Yu L, Okamoto T, Banba Y, Ouchi H,
Takahata H, Asano N. J. Med. Chem. 2005; 48:2036–2044. [PubMed: 15771446] (c) Kuriyama C,
Kamiyama O, Ikeda K, Sanae F, Kato A, Adachi I, Imahori T, Takahata H, Okamoto T, Asano N.
Bioorg. Med. Chem. 2008; 16:7330–7336. [PubMed: 18595718] (d) Shibano M, Tsukamoto D,
Fujimoto R, Masui Y, Sugimoto H, Kusano G. Chem. Pharm. Bull. (Tokyo). 2000; 48:1281–1285.
[PubMed: 10993225] (e) Schitter G, Scheucher E, Steiner AJ, Stutz AE, Thonhofer M, Tarling
CA, Withers SG, Wicki J, Fantur K, Paschke E, Mahuran DJ, Rigat BA, Tropak M, Wrodnigg
TM. Beilstein J. Org. Chem. 2010; 6(f) Paquette LA, Moura-Letts G, Wang GP. J. Org. Chem.
2009; 74:2099–2107. [PubMed: 19173597]
30. Bartoszewicz A, Kalek M, Stawinski J. Tetrahedron. 2008; 64:8843–8850.
31. Wang W, Li XL, Zhang PZ, Chen H. Chin. J. Chem . 2008; 26:208–212.
32. Ko KS, Zea CJ, Pohl NL. J. Am. Chem. Soc. 2004; 126:13188–13189. [PubMed: 15479049]
33. Kleban M, Kautz U, Greul J, Hilgers P, Kugler R, Dong HQ, Jäger V. Synthesis. 2000:1027–1033.
34. Hubschwerlen C. Synthesis. 1986:962–964.
35. Hubschwerlen C, Specklin J, Higelin J. Org. Syn. 1998; 9:454–456.
Lee et al. Page 25













36. (a) Takano S, Kurotaki A, Takahashi M, Ogasawara K. Synthesis. 1986:403–406.(b) Zhong YL,
Shing TKM. J. Org. Chem. 1997; 62:2622–2624. [PubMed: 11671605] (c) Kagawa N, Ihara M,
Toyota M. Org. Lett. 2006; 8:875–878. [PubMed: 16494463]
37. Pandey G, Dumbre SG, Khan MI, Shabab M. J. Org. Chem. 2006; 71:8481–8488. [PubMed:
17064023]
Lee et al. Page 26














Structure of N-butyldeoxynojirimycin (NB-DNJ) and metabolism of glucosylceramide.
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Structures of designed eight-membered iminosugar analogues 1–6.
Lee et al. Page 28














Molecular modeling of ceramide, NB-DNJ and designed compounds 2, 4 and 6.
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X-ray structure of penta-hydroxyazocane 6.
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Structures of designed four-membered iminosugars 22–27.
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Overlay of ceramide, NB-DNJ and designed compounds 23, 25 and 27.
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Km determination for the enzyme/substrate combinations used for glycosidase inhibition
assays (data were fit to the Michaelis-Menten equation).
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a Reagents and conditions: (a) TBSCl, imidazole, DMF, 0 °C to rt, 16 h, 72%; (b) NaH,
benzyl bromide, DMF, rt, 17 h, 72%; (c) TBAF, THF, rt, 16 h, 99%; (d) I2, PPh3, imidazole,
toluene, 70 °C, 3 h, 94%; (e) Zn, THF/H2O, sonication at 40 °C, 2 h, 93%.
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a Reagents and conditions: (a) allylamine, NaBH(OAc)3, ClCH2CH2Cl, rt, 16 h, 86%; (b)
TsCl, TEA, DMAP, CH2Cl2, rt, 3 h, 84%; (c) Grubbs II catalyst, CH2Cl2, reflux, 1 h, 84%.
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a Reagents and conditions: (a) Boc anhydride, DMAP, CH2Cl2, rt, 16 h, 80%; (b) Grubbs II
catalyst, CH2Cl2, reflux, 4 h, 92%.
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Reagents and conditions: (a) Na, naphthalene, DME, −78 °C, 30 min, 75%; (b) 4N HCl in
dioxane, rt, 1 h, 85%; (c) butyraldehyde, NaBH(OAc)3, ClCH2CH2Cl, rt, 16 h, 75%; (d)
nonyl aldehyde, NaBH(OAc)3, ClCH2CH2Cl, rt, 16 h, 76%; (e) PdCl2, MeOH, H2, rt, 16 h,
76% for 1, 78% for 2; (f) Li, liquid NH3, THF, −78 °C, 1 h, 59% for 3, 66% for 4.
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a Reagents and conditions: (a) (DHQ)2-PHAL, K2OsO2(OH)4, K2CO3, K3(FeCN)6,
CH3SO2NH2, THF/t-BuOH/H2O, rt, 40 h, 82%; (b) NaH, BnBr, DMF, rt, 15 h, 87%; (c) Na,
naphthalene, DME, −78 °C, 30 min, 72%; (d) butyraldehyde, NaBH(OAc)3, ClCH2CH2Cl,
rt, 16 h, 79%; (e) nonyl aldehyde, NaBH(OAc)3, ClCH2CH2Cl, rt, 16 h, 84%; (f) PdCl2,
MeOH, H2, rt, 18 h, 80% for 5, 74% for 6.
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a Reagents and conditions: (a) (Carbethoxymethylene)triphenylphosphorane, benzene,
reflux, 74%; (b) DIBAL-H, CH2Cl2, −78 °C to 0 °C, 93%; (c) cumene hydroperoxide, (+)-
DIPT, Ti(OiPr)4, 3Å molecular sieves, CH2Cl2, ,−40 °C, 79%; (d) NaH, benzyl bromide,
TBAI, THF, rt, 1 h, 96%; (e) NaN3, NH4Cl, 2-methoxyethanol–water 9:1, reflux; (f) NaH,
benzyl bromide, TBAI, THF, rt, 1h, 78% over two steps; (g) LiAlH4, THF; (h) tosyl
chloride, triethylamine, CH2Cl2, rt, 90% over two steps. (i) 2N HCl: methanol, 40 °C; (j)
TBSCl, triethylamine, DMAP, CH2Cl2, 85% over two steps; (k) triphenylphosphine, DIAD,
CH2Cl2, rt; (l) Na, naphthalene, DME, −60 °C, 60% over two steps; (m) aldehyde
(butyraldehyde or nonyl aldehyde), sodium triacetoxyborohydride, ClCH2CH2Cl, rt, 70%
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and 72% respectively over two steps; (n) TBAF, THF, rt; (o) PdCl2, H2, methanol, 65% and
70% respectively.
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a Reagents and conditions: (a) NaN3, NH4Cl, 2-methoxyethanol, water 9:1, reflux; (b) NaH,
benzyl bromide, TBAI, THF, rt, 1 h 70% over two steps; (c) LiAlH4, THF; (d) tosyl
chloride, triethylamine, CH2Cl2, rt, 90% over two steps (e) 2N HCl: methanol, 40 °C; (f)
TBSCl, triethylamine, DMAP, CH2Cl2, 89% over two steps; (g) PPhe3, DIAD, CH2Cl2, rt;
(h) Na, naphthalene, DME, −60 °C, 53% over two steps; (i) aldehyde (butyraldehyde or
nonyl aldehyde), sodium triacetoxyborohydride, ClCH2CH2Cl, rt; (j) TBAF, THF, rt 73 and
80% respectively over two steps; (k) PdCl2, H2, methanol, 74 and 80% respectively.
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aReagents and conditions: (a) NaN3, NH4Cl, 2-methoxyethanol, water 9:1, reflux; (b) NaH,
benzyl bromide, TBAI, THF, rt, 1 h, 70% over two steps; (c) LiAlH4, THF; (d) tosyl
chloride, triethylamine, CH2Cl2, rt, 88% over two steps (e) 2N HCl: methanol, 40 °C; (f)
TBSCl, triethylamine, DMAP, CH2Cl2, 87% over two steps; (g) PPhe3, DIAD, CH2Cl2, rt;
(h) Na, naphthalene, DME, −60 °C, 55% over two steps; (i) aldehyde (butyraldehyde or
nonyl aldehyde), sodium triacetoxyborohydride, ClCH2CH2Cl, rt; (j) TBAF, THF, rt 72%
and 76% respectively over two steps; (k) PdCl2, H2, methanol 68% and 74% respectively.
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Table 1
Inhibition of Ceramide-specific Glucosyltransferase and β-Glucosidase 2 by Iminosugar Analogues 1–
6 and 22–27.a
ceramide-specific glucosyltransferase β-glucosidase 2
inhibitor IC50 (C57BL/6, mouse) µM IC50 (LE rat) µM IC50 (LE rat) µM
*NB-DNJ 51b 32 81
1 n.i. n.i. n.i.
2 n.i. n.i. 803
3 n.i. n.i. 1123
4 n.i. n.i. 904
5 n.i. n.i. n.i.
6 n.i. 127 766
22 >300 >300 >300
23 >300 >300 >300
24 >300 >300 >300
25 44 91 >300
26 >300 >300 >300
27 >300 >300 70
a
The details of the enzyme inhibition studies are described in the supporting information; n.i., no inhibition at 1000 µM concentration.
*
NB-DNJ inhibits HL60 cell-derived ceramide-specific glucosyltransferase with an IC50 of 20.4 µM13d and a Ki of 7.4 µM.13a
b
Mouse-derived testicular ceramide-specific glucosyltransferase was inhibited with an IC50 = 23 µM and testicular mouse-derived β-glucosidase 2
with an IC50 = 0.14.10
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